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1 Abbreviations 
1,3-bPG 1,3-bisphosphoglycerat 
ADPR ADP-ribose 
AGE Advanced glycation endproduct 
B2m Beta-2 microglobulin 
Cat Catalase 
CoQ Coenzyme Q 
Ctrl Control 
DAG Diacylglycerol 
DHAP Dihydroxyacetone phosphate 
ETC Electron transport chain 
FAD(H2) Flavin adenine dinucleotide 
FMN Flavin mononucleotice  
Fruc-1,6-bP Fructose-1,6-bisphosphat 
Fruc-6-P Fructose-6-phosphat 
GAP(DH)  Glyceraldehyde 3-phosphate (dehydrogenase) 
Glo Glyoxalase  
Glu-6-P Glucose-6-phosphat 
Gpx Glutathione peroxidase  
HFD High fat diet 
Hprt Hypoxanthine guanine phosphoribosyl transferase 
IHC Immunohistochemistry 
MG Methylglyoxal 
MRS Magnetic resonance spectroscopy 
mt Mitochondrium 
NA Nicotinic acid 
NAD(H) Nicotinamide adenine dinucleotide 
NADP(H) Nicotinamide adenine dinucleotide phosphate 
NNT Number needed to treat 
Nqo1 NAD(P)H quinone reductase  
Nrf2 Nuclear factor, erythroid derived 2, like 2  
O-GlcNAc O-Linked β-N-acetylglucosamine 
PARP Poly(ADP-ribose) polymerase 
PKC Protein kinase C 
Polr2b Polymerase (RNA) II (DNA directed) polypeptide B 
Rn18s 18S ribosomal RNA 
ROS Reactive oxygen species 
Sod Superoxide (O2
-) dismutase 
STZ  Streptozotocin 
T1D Type 1 diabetes 
T2D Type 2 diabetes 
Tbp TATA box binding protein 
TCA Tricarboxylic acid 
Ywhaz Tyrosine 3-monooxygenase 
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2 Introduction 
2.1 What is diabetes? 
Diabetes mellitus is a disorder of glucose homeostasis, which is characterized by 
hyperglycemia. There are different forms of diabetes with the most important forms 
type 1 and type 2.  
Type 1 diabetes (T1D), previously known as juvenile diabetes, is typically diagnosed 
before the age of 30 and accounts for about 5 % of the diabetic patients (Daneman, 
2006). Destruction and loss of the -cells in the pancreas causes insulin-deficiency 
resulting in many changes in the organism, including hyperglycemia (Alberti and 
Zimmet, 1998). The mechanism for the loss of -cells is not fully understood, 
however, it has been suggested that an autoimmune response resulting from a 
combination of genetic and environmental factors, may be the drive force (Davies et 
al., 1994). Patients require regular exogenous insulin administration to control their 
blood glucose levels.  
Type 2 diabetes (T2D), in contrast to T1D, is characterized by the loss of insulin 
sensitivity. The exact mechanism for the development of T2D is not fully understood. 
The pathogenesis seems to be correlated to increased secretion of inflammatory 
cytokines leading to peripheral insulin resistance in particular in the liver and muscle 
(Cai et al., 2005; Spranger et al., 2003). To compensate, the secretion of insulin is 
enhanced (hyposecretion). However, the regulatory mechanism against insulin 
resistance declines over time due to malfunction of the pancreas resulting in 
consecutive hyperglycemia. Depending on the extent of insulin resistance, patients 
with T2D are treated with several drugs including metformin, which improves insulin 
signaling and other drugs such as sulfonylurea and glifozins which stimulate insulin 
secretion and glucose excretion in the kidney (Kahn et al., 2014; Maruthur et al., 
2016).  
Both types of diabetes are associated with long-term complications, which are 
classically subdivided into macrovascular complications (such as cardiovascular 
disease, stroke, cardiac infarction) and microvascular complications (such as 
retinopathy, nephropathy, neuropathy). There is also evidence for vascular-
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independent development of neuropathy (Bierhaus et al., 2012; Eberhardt et al., 
2012). Currently, the exact mechanisms involved in the development of diabetic 
complications are still not fully understood.  
2.2 Can the unifying theory explain diabetic complications? 
It is commonly accepted that hyperglycemia constitutes the very origin in the 
development of diabetic complications. This hypothesis, referred to as the unifying 
theory, is supported by the fact that diabetic complications occur in tissues that take 
in glucose independently from the insulin concentration in the blood, such as 
mesangial cells in the kidney, capillary endothelial cells in the retina, as well as 
neurons and Schwann cells (Brownlee, 2001; Coughlan et al., 2007). During periods 
of hyperglycemia, these cells internalize large amounts of glucose, causing 
supranormal intracellular glucose concentrations. The accumulation of glucose leads 
to increased formation of reactive oxygen species (ROS) in the mitochondria. This 
activates the polyol pathway, the hexosamine pathway as well as protein kinase C 
(and subsequently NFB) and increases the formation of advanced glycation 
endproducts (AGEs), (Figure 1). It has been suggested that the activation of all four 
pathways together gives rise to the cellular dysfunction in diabetes and the 
subsequent development of complications (Brownlee, 2001, 2005; Giacco and 
Brownlee, 2010).  
 
The pathways of cellular dysfunction in the unifying theory 
The accumulation of glucose and the subsequent increase in metabolic flux through 
glycolysis results in increased levels of substrates for the tricarboxylic acid (TCA) 
cycle and oxidative phosphorylation, leading to increased electron flux in the 
electron transport chain (ETC) and overproduction of ROS in the mitochondria. 
Superoxide (O2
-) is the initial ROS formed, but it can be converted into other reactive 
species (see 2.3). If the load of O2
- exceeds the antioxidant capacity of the cell, it 
diffuses into the nucleus where it causes double strand breaks to the DNA. It is, 
however, not feasible to reliably estimate the levels of O2
- produced by the 
mitochondria in vivo (Murphy, 2009). As such, the concentrations, which are 
required to generate oxidative damage to the DNA, remain unknown. Nevertheless, 
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it has been shown, that ROS-induced DNA damage activates the poly(ADP-ribose) 
polymerase (PARP), an enzyme involved in DNA repair (Atorino et al., 2001; Du et al., 
2003; de Murcia et al., 1997). PARP breaks down nicotinamide adenine dinucleotide 
(NAD+) into nicotinic acid (NA) and ADP-ribose (ADPR), then produces polymers of 
ADPR and transfers them to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
thereby deactivating the enzyme (Du et al., 2003; Kanwar and Kowluru, 2009). 
 
Figure 1. Scheme of the unifying theory. Adapted from (Brownlee, 2001). 
 
GAPDH is an enzyme with multiple functions depending on its posttranslational 
modification and cellular localization (Nicholls et al., 2012; Tristan et al., 2011). The 
main function of the homo-tetrameric cytosolic GAPDH complex is the conversion of 
glyceraldehyde 3-phosphate (GAP) to 1,3-biphosphoglycerate (1,3-bPG). Several 
mechanisms for the transport of GAPDH in and out of the nucleus were reported 
including modifications such as acetylation and nitrosylation as well as Golgi 
apparatus mediated transport (Hara et al., 2005; Maruyama et al., 2002; Ventura et 
al., 2010). Once GAPDH is deactivated by poly-ADP-ribosylation, the conversion of 
GAP to 1,3-bPG is reduced, leading to an accumulation of glycolytic metabolites and 
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subsequently activation of the four major pathways of hyperglycemic damage (Du et 
al., 2003, 2000). Studies have demonstrated the inactivation of GAPDH under 
hyperglycemic conditions in vitro (Brownlee, 2005; Du et al., 2003, 2000). Moreover, 
studies in the retina of diabetic animals have shown a decrease in GAPDH activity in 
the progression of retinopathy (Kanwar and Kowluru, 2009; Madsen-Bouterse et al., 
2010). The activity of GAPDH has been shown to be negatively correlated with 
plasma MG levels, which are increased in the progression of nephropathy 
(Beisswenger et al., 2005). However, it remains still unclear whether GAPDH is 
inactivated in the diabetic kidney.  
The loss of GAPDH activity leads to a reduction in glycolysis and an accumulation of 
glucose and the metabolites of glycolysis within the cell. The elevated glucose levels 
are partially converted by aldose reductase into sorbitol, which is then oxidized to 
fructose (polyol pathway). Aldose reductase consumes NADPH, an essential cofactor 
for many reactions to detoxify ROS. The accumulation of sorbitol can result in 
hypertrophy and osmotic stress (Brownlee, 2005; Chung et al., 2003; Dagher et al., 
2004; Lee and Chung, 1999).  
As mentioned, the loss of GAPDH activity leads specifically to an accumulation in the 
metabolites up-stream of the triosephosphates (GAP and dihydroxyacetone 
phosphate, DHAP). The accumulation of these metabolites of glycolysis can be 
diverted into other pathways, for instance, fructose-6-phosphate (Fru-6-P) can be 
diverted into the hexosamine pathway. The end product of this pathway is uridine 
diphosphate N-actelyglucosamine, which is the substrate for posttranslational 
modifications of serine and threonine residues forming O-linked β-N-
acetylglucosamine (O-GlcNAc). The O-GlcNAcylation results in changes in the 
expression of genes, which are associated with the development of diabetic 
complications such as TGF- (Du et al., 2000; Schleicher and Weigert, 2000).  
The accumulation of the triosephosphates can also lead to increased de novo 
synthesis of diacylglycerol (DAG), which enhances the activity of protein kinase C 
(PKC) (Xia et al., 1994). The PKC family consists of several isoforms. In diabetes PKC- 
and PKC-, which require DAG, Ca2+ and phospholipids, and PKC- and PKC-, which 
require only DAG, are elevated. The activation of PKC is linked to the development of 
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late complications due to increase in extracellular matrix synthesis, angiogenesis or 
apoptosis (Geraldes and King, 2010). 
Increased levels of triosephosphates can also result in the increased non-enzymatic 
formation of methylglyoxal (MG) by phosphate elimination (Phillips and Thornalley, 
1993). MG is cytotoxic and preliminary detoxified by the glyoxalase system, which 
consists of glyoxalase I (GLO1) and glyoxalase II (GLO2) (Thornalley, 2003; Vander 
Jagt, 1993). In diabetes, increased formation of MG is associated with decreased 
activity of the glyoxalase system, and linked with the development of diabetic 
complications (Rabbani and Thornalley, 2011; Vander Jagt, 2008). If not detoxified, 
MG mainly reacts with arginine residues forming AGEs (Lo et al., 1994; Rabbani and 
Thornalley, 2012). Intracellular proteins, extracellular matrix proteins and circulating 
proteins can be glycated by MG to form AGEs. The formation of AGEs induces 
damage to the cell by: (1) changed gene transcription, (2) altered interaction 
between matrix components and receptors through the modification of extracellular 
proteins and (3) increased binding of glycated plasma proteins to the receptor for 
AGE (RAGE), leading to a proinflammatory response (Bierhaus et al., 2005; Brownlee, 
2005; Lukic et al., 2008). 
The described pathways are regarded to be activated under hyperglycemic 
conditions by ROS-induced inactivation of GAPDH in all organs which are affected by 
diabetic complications. Yet, the following questions remain unexplained in this 
theory: 
1) Inactivation of GAPDH would lead to a decrease in the substrates of the TCA 
cycle resulting in decreased oxidative phosphorylation and diminished ROS 
production. Can the pathways of hyperglycemic damage be activated in 
diabetes despite this negative feedback mechanism?  
2) Aldose reductase, the first and rate-limiting enzyme in the polyol pathway, 
has a low affinity to glucose (Km of 100 mM) but diabetic endothelial cells 
have a glucose concentration of 30 nmol/mg protein (Bohren et al., 1992; 
Zhang et al., 2003). As such, it is debatable whether glucose can be 
considered as a substrate for aldose reductase in vivo or whether there are 
other mechanisms to activate the polyol pathway. 
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3) The studies underlying the unifying theory have been performed in different 
tissues and in vitro models. However, only few tissues have been examined 
for the activation of all pathways. Therefore, it remains unclear, whether all 
pathways are activated in every tissue, affected by hyperglycemia-induced 
damage. 
2.3 How are ROS produced and how can they be detoxified? 
Oxidative stress is defined as the imbalance between the production of ROS such as 
superoxide (O2
-), hydrogen peroxide (H2O2) and hydroxyl radicals (HO•) and the 
cellular capacity to detoxify these reactive intermediates. Under normal conditions 
ROS function as messengers in redox signaling and mildly increased ROS levels have 
been shown to have health-promoting effects (Ray et al., 2012; Ristow et al., 2009; 
Schmeisser et al., 2013). However, dramatically imbalanced ROS levels lead to the 
disruption of cellular signaling and increased cellular damage.  
There are different sites of ROS production such as the mitochondria, endoplasmic 
reticulum, membranes and peroxisomes. ROS producing enzymes include the 
complexes involved in oxidative phosphorylation, NAD(P)H oxidase, xanthine oxidase 
and lipoxygenase (Aliciguzel et al., 2003; Guzik et al., 2002; Holmström and Finkel, 
2014). According to the unifying theory, increased mitochondrial-derived ROS are 
central to the development of diabetic complications.  
Within the body, 95 % of all inhaled O2 undergoes a concerted four-electron 
reduction to produce water (Halliwell, 2006), (Figure 2). Although the ETC is an 
efficient system, side-reactions with molecular O2 can occur resulting in its reduction 
to O2
-. The primary sites for improper transfer of electrons are complex I and 
complex III of the ETC, however, the O2
- production depends on the local 
concentrations of O2 and electron donors such as NADH and FADH2 (Murphy, 2009). 
On complex I two electrons are transferred in two one-electron steps to the freely 
diffusible electron carrier coenzyme Q (CoQ). It remains under debate which 
component of complex I is the major source of O2
-. The NAD radical, semi-reduced 
CoQ, reduced flavin mononucleotice (FMN) as well as the iron-sulfur cluster are 
postulated to be involved in the production of O2
- under physiological conditions 
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(Kotlyar et al., 1990; Krishnamoorthy and Hinkle, 1988; Kudin, 2003; Kushnareva et 
al., 2002; Kussmaul and Hirst, 2006; Vinogradov and Grivennikova, 2005).  
 
Figure 2. Scheme of the electron transport chain (ETC). Adapted from (Brownlee, 2001). 
 
On complex III the electrons are transferred by asymmetric absorption and released 
within the Q-cycle from the two electron acceptor CoQ to the one electron acceptor 
cytochrome c (Mitchell, 1975). During this asymmetric absorption O2
- can be 
generated. However, it remains under debate whether O2
- is generated in a 
semiforward reaction directly by oxidation of an ubisemiquinone radical or in a 
semireverse reaction transmitted by oxidation of cytochrome b (Drose and Brandt, 
2008; Gille and Nohl, 2001; Muller et al., 2002, 2004; Sarewicz et al., 2010). 
 
Despite the short half-life (1 - 4 µs) and the limited sphere of influence of O2
-             
(1 - 30 nm before it oxidizes a target), this and other ROS can target several cellular 
molecules such as proteins, lipids and DNA causing conformational changes, 
peroxidation, DNA crosslinks as well as strand breaks resulting in oxidative cell 
damage (Birben et al., 2012; Brand et al., 2004; Halliwell, 2006; Jena, 2012). To 
minimize the damaging effects of ROS, the body has evolved a number of 
multifaceted antioxidant defense systems which consist of low-molecular 
scavengers, such as glutathione and vitamins, as well enzymatic antioxidants. The 
major enzymatic antioxidants are superoxide dismutase (SOD) to detoxify O2
-, 
catalase (CAT) to detoxify H2O2, glutathione peroxidase (GPX) to detoxify lipid 
peroxides and esterified peroxyl lipids (Chelikani et al., 2004; McCord and Fridovich, 
1969; Mills, 1957).  
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2.4 Is glucose the right target to treat diabetic complications? 
The unifying theory is based on studies which reported elevated ROS production 
under hyperglycemic conditions in in vitro systems. Subsequent studies reported 
increased oxidative stress also in diabetic patients. The Framingham study measured 
the oxidative stress marker 8-Epi-prostaglandin F2α in the urine and found a positive 
association between systemic oxidative stress and diabetes (Keaney, 2003). 
Oxidative stress, determined as 8-hydroxy-2-deoxy guanosine, was also increased in 
the glomeruli of diabetic patients with nephropathy (Jiang et al., 2010). H2O2 levels 
correlate positively to glycated hemoglobin (HbA1C), an indicator of 3-month average 
plasma glucose, and negatively to uric acid, a systemic antioxidant, in the blood of 
patients with T1D (Francescato et al., 2014). However, with respect to the 
development of complications, plasma and intracellular markers of oxidative stress 
remain unchanged in the blood of T1D patients with and without complications 
(VanderJagt et al., 2001). In T2D, O2
- production was increased in peripheral blood 
mononuclear cells and ROS production was found to be increased in lymphocytes of 
patients with nephropathy (Nam et al., 2008; Widlansky et al., 2010). The majority of 
these studies have only investigated ROS levels in the blood of diabetic patients and 
there have been no conclusive studies in human tissue to this date. 
Hyperglycemia-mediated increase in ROS production and subsequent cellular 
changes are described as the main cause for the development of diabetic 
complications. As such, therapies have focused on the normalization of blood sugar 
and HbA1C. These recommendations are mainly based on the results of the Diabetes 
Control and Complications Trail (DCCT) which consisted of 1441 patients with T1D. It 
was shown that only 11 % of late-complications in T1D patients can be explained by 
the duration of diabetes and the HbA1C levels (DCCT Research Group, 1995). 
Lowering the HbA1C levels, only reduced the absolute risk for albuminuria by 1.4 % 
with the NNT (number needed to treat) of 73.8 patients for 16 years and reduced the 
absolute risk of cardiovascular death by only 2.3 % in 30 years (DCCT/EDIC Research 
Group, 2011). The UKPDS study showed that lowering blood glucose in T2D had no 
effect on the development of cardiovascular complications and decreased the 
absolute risk for microvascular complications by only 2.4 % (UKPDS Study Group, 
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1998). Intensive therapy of T2D patients during the ACCORD study could not reduce 
the risk for microvascular outcomes and even increased mortality and was therefore 
stopped before the end of the study (Ismail-Beigi et al., 2010). In addition, it has 
been shown that the symptoms of diabetic neuropathy can be reduced after gastric 
bypass independent of glucose normalization (Müller-Stich et al., 2013). These 
studies show that the majority of diabetic patients do not benefit from lowering 
blood glucose levels with regard to the development of complications. Therefore, 
hyperglycemia cannot be considered as the only cause for diabetic complications. 
This is further reinforced by studies showing that diabetic complications can already 
develop before the clinical diagnosis of diabetes. In the United States more than      
20 % of patients are already affected by retinopathy when they are diagnosed with 
diabetes and more than 24 % are affected by kidney disease (Harris et al., 1992; 
Plantinga et al., 2010).  
2.5 Can experimental models help to understand diabetes? 
The unifying theory describes glucose-induced increase in mitochondrial ROS 
production as the main cause for cellular damage leading to the development of 
diabetic complications. Oxidative stress is increased in the blood of T1D and T2D, 
however, only a small subset of patients benefit from intensive blood glucose 
lowering therapy. Many experimental studies have tried to analyze functional 
changes of the mitochondria in experimental models to clarify whether 
hyperglycemia affects mitochondrial ROS production and changes the antioxidative 
defense mechanism. The main experimental models to study diabetes are in mice 
and rats. Traditionally, T1D has been induced pharmacological in these models using 
β-cell toxins, such as streptozotocin (STZ) or alloxan. However, in the last decade, 
genetic models have been increasingly used which spontaneously develop diabetes 
due to genetic modifications, such as Ins2+/- Akita mice for T1D or db/db mice for 
T2D. It was shown that with respect to mitochondrial dysfunction in experimental 
diabetes, the results can vary considerably depending on the model, the type of 
diabetes, the organ studied and the methods used (Table 6 –10, Appendix). 
Bugger et al. analyzed mitochondrial function such as ATP production and O2 
consumption in isolated mitochondria of different organs in type 1 diabetic        
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Ins2+/- Akita mice (Bugger et al., 2009). In this study, ATP production remained 
unchanged in heart, liver and kidney. However, O2 consumption was decreased in 
the cardiac mitochondria, unchanged in the hepatic mitochondria and increased in 
the renal mitochondria. In contrast, mitochondrial O2 consumption of kidneys of STZ-
induced Lewis rats remained unchanged after 8 weeks and decreased after 24 and 
48 weeks of diabetes (Rosca et al., 2005). De Cavanagh et al. showed increased 
mitochondrial H2O2 production in isolated renal mitochondria of 12 week diabetic 
STZ-induced Sprague-Dawley rats (de Cavanagh et al., 2008). However, H2O2 
production was decreased in renal mitochondria of wild type mice after 24 weeks of 
diabetes. Using the same model, O2
- production decreased in vivo when analyzed by 
real-time fluorescence imaging (Dugan et al., 2013). Besides the levels of oxidative 
stress, many studies analyzed the levels and activities of antioxidative enzymes, with 
contradictory findings. The activity of SOD1, the cytosolic form of the enzyme, was 
decreased in the heart of 8 week diabetic Wistar rats in one study but remained 
unchanged in the heart of 12 week diabetic Wistar rats in another (Aliciguzel et al., 
2003; Godin et al., 1988). Kakkar et al. showed an increase in CAT activity in the liver 
of Sprague-Dawley rats, 1 week and 6 weeks after the induction of diabetes (Kakkar 
et al., 1998). Yet, using the same model Strother et al. showed decreased CAT after 4 
weeks of diabetes (Strother et al., 2001). In the study of Aliciguzel et al. CAT activity 
was increased in the liver and kidney and decreased in the heart, however, in the 
study of Godin et al. CAT activity behaved oppositely in every tissue (Aliciguzel et al., 
2003; Godin et al., 1988).  
The contradictory results of these studies show that the results depend on the 
methods used as well as on the organ and model organism assessed. As such, these 
studies give no indication whether glucose-induced mitochondrial changes and 
subsequently increased ROS production are associated with the development of 
diabetic complication. Further studies are, therefore, required to clarify the following 
questions:  
1) It is necessary to determine mitochondrial changes using the same 
techniques in all tissues of different diabetic models.  
Introduction 
 12 
2) If changes of the mitochondria are observed, further studies will be required 
to determine whether glucose or other metabolites of glycolysis are 
responsible for the induction of mitochondrial changes. These studies are 
fundamental as intervention studies found only a minor association between 
blood glucose and the development of diabetic complications.  
2.6 What is the aim of the study? 
As shown, diabetes is a complex disease, which is still not completely understood 
and many studies point out that hyperglycemia cannot be considered as the only 
factor involved in the pathogenesis of diabetic complications (Nawroth et al., 2010). 
The unifying theory, which is the predominant theory for the development of 
diabetic complications, is centered on glucose-induced increase in mitochondrial 
ROS production which leads to cellular damage. If this theory was correct, all 
complications would develop by the same mechanism and patients suffering from 
one complication would also be affected by the other complications. However, 
based upon the clinical evidence, diabetic patients tend to be more heterogeneous 
with respect to complications and different organs show distinct symptoms during 
the course of the disease. Thus, it needs to be analyzed whether the unifying theory 
can be applied to the development of all diabetic complications. Many studies have 
already analyzed changes in mitochondrial function in diabetes. However, as many 
different approaches have been used to assess mitochondrial function, the results 
have not been conclusive. Thus, this study was performed to determine the 
consistency of the effect of 3 months diabetes on the mitochondria in different 
tissues and 2 different mouse models (STZ and db/db), using standardized 
techniques. To assess different organs, the heart was chosen as a model for 
macrovascular complications, the kidney as a model for microvascular complications 
and the liver as an organ, which is classically not affected by diabetic complications.  
Moreover, the activation of the four pathways of cellular dysfunction, as described 
by the unifying theory, were analyzed in the kidney as damage to this organ can be 
determined non-invasively by measurements of albumin secretion in the urine. 
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3 Material and Methods 
3.1 Mouse models 
Animal studies were approved by the Animal Care and Use Committee at the 
regional authority in Karlsruhe, Germany (file numbers: 35-9185.81/G-3/15, 35-
9185.81/G-33/15, T-94/14). Male wild type mice (C57BL/6N) were obtained from 
Charles River, Sulzfeld, Germany. With about 3 months of age, diabetes type 1 was 
induced in wild type mice by intraperitoneal administration of streptozotocin (STZ, 
60 mg/kg) for 5 consecutive days (Like and Rossini, 1976). Blood glucose was 
measured weekly using a glucometer and adjusted with insulin glargin (Lantus®, 
Sanofi) to <350 mg/dl. Male C57BL/6N-Leprdb in the following only called db/db mice 
were kindly provided by the department of Cardiology, University Clinic Heidelberg. 
Db/db mice are homozygous for the diabetes mutation Leprdb and develop type 2 
diabetes at 4 weeks of age without the need for insulin treatment (Hummel et al., 
1966). All mice were housed in groups with up to 4 animals in temperature- and 
humidity-controlled rooms (22°C, 55 %) with 12 h / 12 h light / dark cycle and given 
water and food ad libitum.  
Mice were sacrificed by CO2 inhalation and directly perfused through the heart via 
the vascular system using ice cold PBS. Heart, liver and kidney were dissected and 
either divided and flash-frozen in liquid nitrogen or used fresh for isolation of 
mitochondria. 
3.2 Immunohistochemistry 
Immunohistochemistry (IHC) was performed at the Institute of Pathology, 
Heidelberg. Tissue pieces (0.5 cm x 0.5 cm) were thawed and directly transferred 
into 4 % formalin and fixed at RT for 24 h. Fixed tissues were embedded into paraffin 
using the standard routine diagnostic protocol of the institute. Paraffin blocks were 
cut into 1 µm thick tissue sections using a HM 340E Rotary Microtome (Thermo 
Scientific Fisher) and mounted on glass microscope slides. Tissue sections were 
stained with hematoxylin and eosin (HE), Alcian blue/periodic acid–Schiff (AB-PAS) 
Masson’s trichrome (trichrome) following routine diagnostic standard protocols of 
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the institute. Images were acquired with 20x magnification using a Hamamatsu 
NanoZoomer Digital Pathology system and analyzed using ObjectiveView 2. 
3.3 Physiological parameters 
All spectrophotometrical and flurometric assays were carried out using a BMG 
Labtech FLUOstar Omega multiplate reader.  
3.3.1 Albumin secretion 
Urine was collected for 4 h in metabolic cages and diluted 1:350. Albumin was 
determined using Mouse Albumin Elisa Kit, Immunology Consultants Laboratory and 
the protein concentration was determined using Bradford reagent (Bradford, 1976). 
Daily albumin secretion was calculated as µg albumin/24 h/g bodyweight.  
3.3.2 Plasma cystatin C 
Plasma samples were diluted 1:2,500 and cystatin C levels were determined using a 
commercially available Mouse Cystatin C Elisa Kit (RayBio®). 
3.4 Mitochondrial function 
3.4.1 Isolation of mitochondria 
Mitochondria were isolated according to Cox and Emili with slight modifications (Cox 
and Emili, 2006). Briefly, tissue was homogenized in ice-cold isolation buffer I (250-
STMDPS) containing 250 mM mannitol, 50 mM Tris (pH7.4), 5 mM MgCl2, 1 mM DTT 
and 1 % protease inhibitor cocktail (P9599, Sigma) using a tight fitting teflon pestle. 
To isolate cardiac mitochondria 1 mg/ml collagenase IV was added to the extraction 
buffer. The lysate was centrifuged (800 g, 4 °C, 15 min, 3x). The supernatant served 
as a source for the mitochondria and was resuspended in isolation buffer II 
containing 280 mM mannitol, 10 mM MgCl2, 5 mM K2HPO4, 10 mM MOPS, 1mM 
EGTA, pH 7.4 and centrifuged (6,000 g, 4°C, 15 min, 3x). Isolated mitochondria were 
resuspended in respiration buffer containing 250 mM sucrose, 15 mM KCl, 1 mM 
EGTA, 5 mM MgCl2, 30 mM K2HPO4, pH 7.4 and protein concentration was 
determined using the Lowry protein assay (Lowry et al., 1951). Mitochondria were 
kept on ice and functional assays were performed within 4 h after isolation. 
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3.4.2 Purity of the mitochondria 
Isolated mitochondria (100 µg) were stained with 300 nM MitoTracker® Green FM 
(M7514, ThermoFisher Scientific) in the dark at 37°C for 30 min. Subsequently, the 
mitochondria were washed 3 times and analyzed using a BD FACSCanto II system. 
The mitochondrial fraction showed a purity of more than 95 %.  
3.4.3 ATP production 
ATP production was determined using the ATPlite Luminescence Assay System 
(Perkin Elmer). Freshly isolated mitochondria were diluted in respiration buffer (see 
4.3.1) and 0.5 µg isolated mitochondria, 12.5 mM malate, 12.5 mM glutamate and 
1.65 mM ADP were added to a 96-well white microplate to measure state 3 
respiration using malate, the substrate for complex I. State 3 respiration was also 
measured using succinate, the substrate for complex II. Therefore, 0.5 µg isolated 
mitochondria, 25 mM succinate and 1.65 mM ADP were added to a white 
microplate. After addition of the substrates, the plate was incubated for 8 min at 
37°C on a heating plate. Meanwhile ATP standard 0.5 – 10 nmol were prepared in 
100 µl respiration buffer and added to the plate. After incubation ATPlite Assay was 
performed by adding 50 µl of cell lysis buffer followed by 50 µl of substrate solution. 
The plate was shaken for 5 min and dark equilibrate for 5 – 10 min before the 
luminescence was measured.  
3.4.4 Mitochondrial O2 consumption 
O2 consumption was determined according to Will et al. using MitoXpress® Xtra, 
Luxcel Bioscience (Will et al., 2007). Freshly isolated mitochondria were diluted in 
respiration buffer (see 4.3.1). All reagents were warmed to 37°C and the microplate 
was prepared on a warming plate. To each well 100 µl MitoXpress probe 
reconstituted in 10 ml respiration buffer (see 3.4.1) and 50 µg isolated mitochondria, 
12.5 mM malate, 12.5 mM glutamate and 1.65 mM ADP were added to a 96-well 
clear bottom black microplate to measure state 3 respiration using malate, the 
substrate for complex I. State 3 respiration was also measured using succinate, the 
substrate for complex II. Therefore, 25 µg isolated mitochondria, 25 mM succinate 
and 1.65 mM ADP were added to a clear bottom black microplate. Time-resolved 
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fluorescence (TRF) measurements were performed using a TRF reading head with a 
distance of 6 mm and applying 380 nm (excitation) and 655 nm (emission). The gain 
was set to 2,200 and the delay to 30 µs and 70 µs with of constant gate time of 30 
µs. Data were processed according to Will et al. and the slope of the linear range was 
calculated.  
3.4.5 O2
- production 
O2
- production was measured using nitrotetrazolium blue chloride (NBT, Sigma-
Aldrich), (Sim Choi et al., 2006). Freshly isolated mitochondria were diluted in 
respiration buffer and 15 µg were added in a 96-well clear microplate (see 4.3.1). 
250 µl NBT in respiration buffer, 12.5 mM malate, 12.5 mM glutamate and 1.65 mM 
ADP were added to measure state 3 respiration using malate, the substrate for 
complex I. State 3 respiration was also measured using succinate, the substrate for 
complex II. Therefore, 25 mM succinate and 1.65 mM ADP were added to the 
mitochondria. The plate was incubated for 90 min at 37°C followed by a 
centrifugation step (4,000 rpm, RT, 5 min). The supernatant was discarded by 
inversion of the plate and applying a sharp flick of the wrist. The plate was gently 
tapped dry on paper towels and 200 µl of DMSO were added to dissolve the blue 
NBT formazan deposits. Absorbance spectrum (400 – 900 nm) was read and maximal 
absorbance was corrected for minimal absorbance. 
3.4.6 H2O2 production 
H2O2 production was measured using H2DCFDA (Thermo Fisher Scientific). Freshly 
isolated mitochondria were diluted in respiration buffer and 2.5 µg mitochondria as 
well as 5 µM H2DCFDA were added in a 96-well black microplate (see 4.3.1). To 
measure state 3 respiration with substrates for complex I and II, 12.5 mM malate, 
12.5 mM glutamate and 1.65 mM ADP or 25 mM succinate and 1.65 mM ADP were 
added and the increase in fluorescence was measured over 30 min applying 485 +/- 
12 nm (excitation), 520 nm (emission) and a gain of 1,500. The slope of the linear 
range was calculated as RFU/min. 
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3.5 Enzymatic Assays 
3.5.1 Protein isolation  
Flash frozen tissue was grounded using an ice-cold mortar and 10 mg of tissue were 
resuspended in 200 µl of hypotonic buffer containing 50 mM K2PO4 and 10 mM 
MgCl2 and sonicated twice with 10-15 % for 15 sec. Samples were then centrifuged 
(14,000 rpm, 4°C, 10 min) and the protein concentration of the supernatant was 
determined using the Bradford assay (Bradford, 1976). 0.5 - 8 µg tissue per well were 
used to determine CAT, GLO1, NQO1 and SOD activity in a 96-well plate format using 
a clear microplate unless otherwise indicated.  
3.5.2 CAT activity 
CAT activity was determined as the rate of disappearance by detecting the decrease 
in the absorbance of 240 nm using 0.036 % (w/w) H2O2 in 50 mM potassium 
phosphate buffer, pH 7.0 and an UV-transparent microplate (Beers and Sizer, 1952). 
3.5.3 GLO1 activity 
Glo1 activity was determined using the method described by Thornalley measuring 
the increase of absorbance at 240 nm and 37 °C due to S-D-lactoylglutathione 
formation from hemithioacetal generated by pre-incubation of MG and GSH at 37 °C 
for 10 min (Thornalley, 1988). 
3.5.4 NQO1 activity 
NQO1 activity was determined as the rate of increase in the absorbance of formazan 
at 650 nm. A reaction mixture containing glucose-6-phosphate and glucose-6-
phosphate dehydrogenase continuously generated NADPH. This was used by NQO1 
to reduce menadione which subsequently MTT to a blue formazan (Prochaska and 
Santamaria, 1988). To validate the measurement of NQO1 activity, the assay was 
also performed with 0.3 mM of the NQO1 inhibitor dicumarol (Sigma Aldrich) per 
well (He et al., 2006).  
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3.5.5 SOD activity 
SOD activity was determined according to McCord and Fridovich by measuring the 
inhibition of the decrease in absorbance at 550 nm due to the reduction of 
cytochrome c (10 mM) by O2
- radicals, which were produced by a coupled enzymatic 
reaction of xanthine oxidase (1.5 mU/ml) with atomar oxygen (McCord and 
Fridovich, 1969).  
3.5.6 GAPDH activity 
GAPDH activity was determined in cytosolic and nuclear extracts of kidney samples 
(see 3.7.2) measuring the increase in absorbance due to the reduction of NAD 
(Bergmeyer et al., 1974). 15 µg of protein were mixed with the reaction buffer 
containing 83 mM triethanolamine, 6.7 mM 3-phosphoglyceric acid, 3 mM L-
cysteine, 2 mM MgSO4, 0.1 mM NADH, 1.1 mM ATP and 3.3 U/ml 3 phosphoglyceric 
phosphokinase in a UV-transparent microplate and the increase in absorbance was 
measured at 340 nm for 10 min. To measure nuclear GAPDH activity 15 µg as well as 
30 µg protein were used.  
3.5.7 PKC activity 
Flash frozen tissue was grounded using an ice-cold mortar and 10-20 mg of tissue 
were homogenized in PKC extraction buffer containing 25 mM Tris-HCl pH 7.4, 0.5 
mM EDTA, 0.5 mM EGTA, 10 mM -mercaptoethanol, 1 % protease inhibitor cocktail 
(P9599, Sigma). Samples were centrifuged (14,000 rpm, 4°C, 10 min) and the 
supernatant was transferred to a pre-equilibrated HiTrapDEAD FF 1 ml column (GE 
Healthcare). The samples were washed with 5 ml PKC extraction buffer applying a 
flow rate of 1 ml/min. The samples were eluted using 5 ml PKC extraction buffer 
containing 200 mM NaCl, drop 32 – 58 were collected and the samples were stored 
at -80°C until analyzed. After thawing, the protein concentration of the eluate was 
determined using Bradford reagent (Bradford, 1976). The Activity was analyzed 
according to the manufacture’s protocol (PKC kinase activity kit, Enzo Life Science) 
using 4.5 µg protein per well. Absorbance was measured at 450 nm and corrected 
for 570 nm.  
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3.6 Expression analysis 
3.6.1 RNA extraction and cDNA synthesis  
Flash frozen tissue was grounded using an ice-cold mortar and 10-20 mg of tissue 
were homogenized in RNA lysis buffer. The subsequent extraction was performed 
according to the manufactures protocol (PeqGold Total RNA Kit, Peqlab). 
Quantification of RNA was performed using a photometer (Eppendorf, GmbH). A 
total of 2 µg of RNA were used for the cDNA synthesis reaction and performed 
according to the manufactures protocol (High-capacity cDNA Reverse Transcription 
Kit, Thermo Fisher Scientific).  
3.6.2 Quantitative real-time PCR 
cDNA was diluted 1:6 with H2O and used for qPCR analysis performed in duplicates 
with DyNAmo Flash SYBR Green qPCR Kit (Biozym). Briefly, 1 µl of cDNA was 
transferred into a 96-well qPCR microplate and 10 µl of reaction mix containing 1 x 
SYBR Green Mastermix, 200 nM forward primer and 200 nM reverse primer 
(Eurofins Genomics), (Table 8).  
 
Table 1. Primer 
Gene Gene ID Sequence [5'  3'] 
Amplicon 
size, bps 
B2m 12010 
for 
rev 
TTCTGGTGCTTGTCTCACTGA 
CAGTATGTTCGGCTTCCCATTC 
104 
Cat 12359 
for AGCGACCAGATGAAGCAGTG 
181 
rev TCCGCTCTCTGTCAAAGTGTG 
Glo1 109801 
for GATTTGGTCACATTGGGATTGC 
110 
rev TCCTTTCATTTTCCCGTCATCAG 
Gpx1 14775 
for AGTCCACCGTGTATGCCTTCT 
105 
rev GAGACGCGACATTCTCAATGA 
Gpx4 625249 
for GCCTGGATAAGTACAGGGGTT 
99 
rev CATGCAGATCGACTAGCTGAG 
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Gene Gene ID Sequence [5'  3'] 
Amplicon 
size, bps 
Hprt 15452 
for 
rev 
TCAGTCAACGGGGGACATAAA 
GGGGCTGTACTGCTTAACCAG 
142 
Nqo1 18104 
for AGGATGGGAGGTACTCGAATC 
144 
rev AGGCGTCCTTCCTTATATGCTA 
Nrf2 18024 
for TCTTGGAGTAAGTCGAGAAGTGT 
140 
rev GTTGAAACTGAGCGAAAAAGGC 
Polr2b 231329 
for 
rev 
GACGACGATGAGATCACTCCG 
GGTGCATCTTCCACAATTCTTTG 
152 
Rn18s 19791 
for 
rev 
CGGCTACCACATCCAAGGAA 
GCTGGAATTACCGCGGCT 
187 
Sod1 20655 
for AACCAGTTGTGTTGTCAGGAC 
139 
rev CCACCATGTTTCTTAGAGTGAGG 
Sod2 20656 
for CAGACCTGCCTTACGACTATGG 
113 
rev CTCGGTGGCGTTGAGATTGTT 
Tbp 21374 
for 
rev 
AGAACAATCCAGACTAGCAGCA 
GGGAACTTCACATCACAGCTC 
120 
Ywhaz 22631 
for 
rev 
GAAAAGTTCTTGATCCCCAATGC 
TGTGACTGGTCCACAATTCCTT 
134 
 
The plate was sealed with a film and centrifuged (1000 rpm, 4°C, 1 min). 
Quantitative real-time PCR analysis was performed using Roche Lightcycler 480 
applying the following protocol (Table 9).  
The cross-points (Cp) were calculated and the relative ratio of the mRNA levels were 
determined applying the following formula 2 x (2 Cp(target)-Cp(reference))-1 and using the 
geometric mean of the Cp values of B2m, Hprt, Polr2b, Rn18s, Tbp, Ywhaz as a 
reference (Hruz et al., 2011; Svingen et al., 2015). 
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Table 2. Thermocycler protocol for qPCR 
Step Temperature, °C Time 
Ramp rate, 
°C/sec 
Number of 
cycles 
Pre-incubation 95 7 min 4.4 1 
Amplification 
95 10 sec 4.4 
45 60 20 sec 2.2 
72 1 sec 4.4 
Melting curve 
95 5 sec 4.4 
1 65 1 min 2.2 
97 5 acquisitions per °C 0.11 
Cooling 4 forever 4.4 1 
 
3.7 Immunoblotting 
3.7.1 Whole tissue protein extracts 
For whole tissue lysis, flash frozen tissue was grounded using an ice-cold mortar and 
10 – 20 mg grounded tissue were resuspended with a syringe in RIPA buffer 
containing 50mM Tris-HCl pH 7.5, 150 mM NaCl, 1 % Triton X-100, 0.5 % Na-
deoxycholate, 0.1 % SDS, 1 mM DTT, 1 % protease inhibitor (P9599, Sigma) and 40 
U/ml benzonase (Millipore). The samples were incubated on ice for 1 h with periodic 
vortexing and centrifuged (14,000 rpm, 4°C, 30 min). Protein concentration of the 
supernatant was determined using Bradford reagent and the samples were stored at 
-20°C until used (Bradford, 1976).  
3.7.2 Cytoplasmic and nuclear protein extracts 
Flash frozen tissue was grounded using an ice-cold mortar and 20 mg grounded 
tissue were resuspended in lysis buffer containing 10 mM HEPES pH 7.9, 1.5 mM 
MgCl2, 10 mM KCl, 0.5 mM DTT, 0.05 % NP40 and 1 % protease inhibitor cocktail 
(P9599, Sigma). The samples were vortexed, incubated on ice for 10 min and 
subsequently centrifuged (3,000 rpm, 10 min, 4°C). The supernatant containing the 
cytoplasmic fraction was transferred to a new tube and the pellet was washed with 
lysis buffer until clear, before resuspending it in nuclear buffer containing 5 mM 
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HEPES pH 7.9, 1.5 mM MgCl2, 500 mM NaCl, 0.2 mM EDTA, 0.5 mM DTT, 26 % 
glycerol and 1 % protease inhibitor cocktail. The samples were vortexed, incubated 
on ice for 20 min and sonicated at 10-15 % power for 10 sec twice. The samples were 
centrifuged (14,000 rpm, 4°C, 10 min) and the supernatant containing the nuclear 
fraction was transferred to a new tube. Protein concentration of cytoplasmic and 
nuclear fraction was determined using Bradford reagent (Bradford, 1976). 
3.7.3 Immunoblotting 
About 10-30 µg protein were mixed with Laemmli buffer containing 0.8 % SDS, 4 % 
glycerol, 100 mM DTT, 25 mM Tris-HCl pH 6.8, 0.005 % bromophenol blue and 
cooked at 95°C for 10 min (Laemmli, 1970). Proteins were resolved by SDS-PAGE (4-
15 % Mini-PROTEAN TGX, Biorad) applying 180 V for 45 min and transferred onto a 
nitrocellulose membrane applying 25 V for 27 min. Transfer was checked using 
Ponceau Red and membranes were blocked using 2 % milk powder in PBS-T or in the 
case of O-GlcNAc with Pierce Protein-Free Blocking Buffer (Thermo Scientific Fisher). 
After 1 h blocking at RT, the primary antibody was added in the appropriate 
concentration (Table 10). After overnight incubation at 4°C the blots were washed 
with PBS-T and incubated with the secondary antibodies coupled to horseradish 
peroxidase (Table 11) for 1 h at RT. The proteins were detected using ECL reagent 
(GE Healthcare). For reprobing, membranes were stripped in a 80°C water bath for 
20 min using 0.2 M glycine pH 2.5 and 0.05 % Tween 20. Afterwards the membranes 
were washed with PBS-T, blocked and processed as mentioned above. Images were 
acquired and quantified using the GS-800 calibrated densitometer and Quantity 
One  1-D analysis software, Bio-Rad.  
Table 3. Primary antibodies 
Antibody for Isotype Company Dilution 
CAT Rabbit 14097, Cell Signaling Technology 1: 3,000 
GAPDH Rabbit 181602, abcam 1: 10,000 
GLO1 Rat 81461, abcam 1: 1,500 
Histone H3 Rabbit 4499, Cell Signaling Technology 1: 3,000 
Material and Methods 
 23 
Antibody for Isotype Company Dilution 
NQO1 Mouse 28947, abcam 1:3,000 
O-GlcNAc Mouse 677902, Biolegend 1: 1,000 
PKC- Mouse 8393, Santa Cruz Biotechnology 1:500 
PKC- Rabbit 937, Santa Cruz Biotechnology 1:500 
SOD1 Mouse 20926, abcam 1: 1,500 
SOD2 Rabbit 13533, abcam 1:5,000 
 
As the common cytosolic loading controls -actin and GAPDH were increased in the 
kidney of both diabetic models, the nuclear specific loading control histone H3 was 
used for whole tissue protein extracts. 
Table 4. Secondary antibodies 
Antibody for Company Dilution 
Mouse 7076, Cell Signaling Technology 
twice the dilution of 
the first antibody  
Rabbit 7074, Cell Signaling Technology 
Rat 7077, Cell Signaling Technology  
3.8 Metabolomics 
3.8.1 Determination of adenosine compound levels 
Adenosine compounds were extracted from freshly grounded renal tissue              
(15-25 mg) with 0.25 ml ice-cold 0.1 M HCl in an ultrasonic ice-bath for 10 min. The 
resulting homogenates were centrifuged (16,400 g, 4°C, 10 min) to remove cell 
debris. Adenosines were derivatized with chloroacetaldehyde as previously 
described and separated by reversed phase chromatography on an Acquity BEH C18 
column (150 mm x 2.1 mm, 1.7 µm, Waters) connected to an Acquity H-class UPLC 
system (Bürstenbinder et al., 2007). Prior separation, the column was heated to 42°C 
and equilibrated with 5 column volumes of buffer A (5.7 mM TBAS, 30.5 mM KH2PO4 
pH 5.8) at a flow rate of 0.45 ml/min. Separation of adenosine derivates was 
achieved by increasing the concentration of buffer B (2/3 acetonitrile in 1/3 buffer A) 
in buffer A as follows: 1 min 1 % B, 1.6 min 2 % B, 3 min 4.5 % B, 3.7 min 11 % B, 
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10min 50 % B, and return to 1 % B in 2 min. The separated derivates were detected 
by fluorescence (Acquity FLR detector, Waters, excitation: 280 nm, emission: 410 
nm) and quantified using ultrapure standards (Sigma). Data acquisition and 
processing was performed with the Empower3 software suite (Waters).  
Adenosine compound levels were kindly quantified by Dr. Gernot Poschet at the 
Centre for Organismal Studies (COS), University Heidelberg. 
3.8.2 Determination of organic acid and sugar levels 
Organic acids and sugars were extracted of 15-25 mg grounded tissue using 400 µl 
ultra-pure water and heated at 95°C for 20 min. Organic acids were separated using 
an IonPac AS11-HC (2mm, ThermoScientific) column connected to an ICS-5000 
system (ThermoScientific) and quantified by conductivity detection after cation 
suppression (ASRS-300 2mm, suppressor current 95-120 mA). Prior separation, the 
column was heated to 30°C and equilibrated with 5 column volumes of solvent A 
(ultra-pure water) at a flow rate of 0.38 ml/min. Separation of anions and organic 
acids was achieved by increasing the concentration of solvent B (100mM NaOH) in 
buffer A as follows: 8 min 4 % B, 18 min 18 % B, 25 min 19 % B, 43 min 30 % B, 53 
min 62 % B, 53.1 min 80 % B for 6 min, and return to 4 % B in 11 min. Soluble sugars 
were separated on a CarboPac PA1 column (ThermoScientific) connected to the ICS-
5000 system and quantified by pulsed amperometric detection (HPAEC-PAD). 
Column temperature was kept constant at 25°C and equilibrated with 5 column 
volumes of solvent A (ultra-pure water) at a flow rate of 1 ml/min. Baseline 
separation of carbohydrates was achieved by increasing the concentration of solvent 
B (300mM NaOH) in solvent A as follows: From 0 to 25 min 7.4 % B, followed by a 
gradient to 100 % B within 12 min, hold for 8 min at 100 % B, return to 7.4 % B and 
equilibration of the column for 12 min. Data acquisition and quantification was 
performed with Chromeleon 7 (ThermoScientific) (Neubert et al., 2016). 
Organic acid and sugar levels were quantified by Dr. Gernot Poschet at the Centre 
for Organismal Studies (COS), University Heidelberg. 
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3.8.3 Determination of MG levels 
The concentration of MG was determined by stable isotope dilution analysis liquid 
chromatography with tandem mass spectrometric detection (LCMSMS), as described 
previously (Rabbani and Thornalley, 2014). Briefly, 10 mg of tissue were 
deproteinized by addition of 10 µl of 20 % trichloroacetic acid. The internal standard, 
2 pmol of [13C2]-MG (prepared in-house), were added and MG derivatized by 
incubation with 100 µM 1,2-diamonbenzene, 100 µM diethylenetriaminepenta-
acetic acid, 5 mM sodium dithionite stabilizer and 0.3 % (w/v) NaN3 in the dark at RT 
for 4 h (Dobler et al., 2006; Thornalley and Rabbani, 2014). Samples were assayed by 
LC-MS/MS using an ACQUITY UPLC-I class with a Xevo TQ-S mass spectrometric 
detector, Water Cooperation. Samples were separated using a BEH C18 column 
(ACQUITY, 1.7 μm, 100 x 2.1 mm, Waters Corporation) fitted with a pre-column 
(ACQUITY, 1.7 μm, 5 x 2.1 mm, Waters Corporation). The mobile phase was 0.1 % 
formic acid with a linear gradient of 0-100 % of 0.1 % formic acid in 50 % (v/v) 
acetonitrile over 10 min at a flow rate of 0.2 ml/min. The column was washed with 
100 % of 0.1 % formic acid in 50 % (v/v) acetonitrile and re-equilibrated with 100 % 
of 0.1 % formic acid. The analysts were detected by positive ionization with multiple 
reaction monitoring with a retention time of 5.9 min. Mass transition (parent ion > 
fragment ion; collision energy; cone voltage) were: MG 145.01 > 77.10; 24 eV; 2 V & 
[13C2]-MG 148.06 > 77.16; 24 eV; 2 V. Other mass spectrometer settings were: 
capillary voltage 0.5 kV, source temperature 150 °C, desolvation gas temperature 
350 °C, desolvation gas flow 800 l/h and cone gas flow 150 l/h. A calibration curve 
was constructed from 0-20 pmol of MG. The limit of detection was 0.520 pmol.  
3.9 Statistical analysis 
All statistical analyses were performed in GraphPad Prism 7 and the level for 
statistical significance was defined as p < 0.05. Outlier elimination was performed 
applying Tuckey’s method of leveraging the interquartile range (Tukey, 1977). The 
function of the mitochondria was assessed using one control and one diabetic 
mouse per day. To minimize day-to-day variation, mitochondrial function was 
analyzed separately for each day. The mean of the control measurements for each 
day was normalized to 1 and the diabetic measurements were calculated as an 
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arithmetical ratio to the respective control. Differences between data groups of 
mitochondrial function were evaluated for significance using one-sample t-test. 
Significance of all other measurements was calculated using unpaired t-test 
assuming Gaussian distribution. 
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4 Results 
4.1 Tissue specific changes in the function of the mitochondria of type 
1 and type 2 diabetic mice 
4.1.1 Physiological characterization of the experimental models 
Type 1 and type 2 diabetic mouse models on the C57BL/6N background were 
analyzed for diabetes-induced functional changes of the mitochondria. T1D was 
induced to male wild type mice (C57BL/6N) by intraperitoneal administration of the 
-cell toxin STZ at about 3 months of age. Blood glucose levels were increased in the 
diabetic mice (BL6-STZ) compared to the age-matched, non-diabetic littermates 
(BL6-ctrl) and weekly adjusted with insulin to < 350 mg/dl. On the day of sacrifice the 
plasma glucose levels were determined as 188 +/- 43 mg/dl for the BL6-ctrl mice vs 
402 +/- 130 mg/dl for the BL6-STZ mice, p < 0.001 (Table 5). T2D was studied in 
db/db mice on the C57BL/6N background, which were homozygous for the diabetes 
mutation Leprdb, and age-matched non-diabetic littermates (db/m). The db/db 
animals developed diabetes spontaneously at about 4 weeks without the need for 
insulin treatment. On the day of sacrifice the plasma glucose levels were determined 
as 169 +/- 20 mg/dl for the db/m mice vs 300 +/- 29 mg/dl for the db/db mice, p < 
0.001 (Table 5). After induction of diabetes the BL6-STZ mice stopped increasing 
weight resulting in a decreased bodyweight compared to the controls (35.7 +/- 2.5 g 
vs 23.8 +/- 3.0 g, p < 0.001). In contrast, the db/db mice gained more weight than 
their respective controls (24.8 +/- 1.6 vs 47.6 +/- 1.5 g, p < 0.001). The differences in 
bodyweight were also reflected in changed wet weights of several tissues; the heart 
of the BL6-STZ mice showed a decreased wet weight (0.13 vs 0.18 g, p < 0.001) and 
the liver of the db/db mice showed an increased wet weight when compared to the 
controls (1.6 +/- 0.3 vs 4.8 +/- 1.2 g, p < 0.001). IHC stainings of the liver showed local 
cellular infiltration in the BL6-STZ mice indicating mild inflammation (Figure 3, blue 
arrow). IHC stainings of the enlarged liver of the db/db mice showed an 
accumulation of fat droplets indicating hepatic steatosis (Figure 3, yellow arrow), 
which was not accompanied by inflammation or fibrosis as assessed by HE, AB-PAS 
and trichrome stainings (Figure 3).  
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Table 5. Basic and physiological parameters of the experimental animals 
 
Type 1 diabetes  Type 2 diabetes  
Nomenclature 
control 
BL6-ctrl 
diabetic 
BL6-STZ  
control 
db/m 
diabetic 
db/db  
Age of animals, d 203 +/- 13 
 
130 +/- 16 
 
Duration of diabetes, d 0 121 +/- 29 
 
0 110 +/- 16 
 
Plasma glucose, mg/dl 188 +/- 43 402 +/- 130 *** 169 +/-20 300 +/- 29 *** 
Bodyweight (BW), g 35.7 +/- 2.5 23.8 +/- 3.0 *** 24.8 +/- 1.6 47.6 +/- 1.5 *** 
Wet weight of heart, g 0.18 +/- 0.0 0.13 +/- 0.0 *** 0.13 +/- 0.0 0.14 +/- 0.0 
 
Wet weight of liver, g 1.7 +/- 0.3 1.6 +/- 0.4 
 
1.6 +/- 0.3 4.8+/- 1.2 *** 
Wet weight of kidney, g 0.54 +/- 0.0 0.58 +/- 0.1 
 
0.44 +/- 0.1 0.43 +/- 0.1 
 
Albumin in urine,  
µg/24 h/g BW 
0.4 +/- 0.4 1.4 +/- 0.5 *** 0.7 +/- 0.5 1.9 +/- 0.6 * 
Plasma cystatin C, µg/ml 5.4 +/- 0.6 4.5 +/- 0.6 * 5.1 +/- 0.7 5.4 +/- 0.6 
 
 
Data are expressed as mean +/- SD. For type 1 and type 2 diabetic study groups n = 10 and 9, 
respectively. For statistical analysis two sided t-test was applied * p < 0.05 and *** p < 0.001 vs 
non-diabetic control. 
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Figure 3. IHC stainings of the liver: inflammation and steatosis in the diabetic liver 
Representative photomicrographs of liver sections are shown. Of each 
experimental group 3 livers  were stained with hematoxylin and eosin (HE), Alcian 
blue/periodic acid–Schiff (AB-PAS) and (Masson’s) trichrome. The blue arrow 
indicates cellular infiltration and the yellow arrow indicates fat droplets. Original 
magnification x20.  
IHC stainings were performed in the kidney and glomeruli, showing vas afferens and 
efferens, were assessed. The Bowman’s capsule of the control mice was filled with 
parietal epithelial cells (Figure 4, orange arrow), however, the cells within the 
capsule were missing in the BL6-STZ mice, leaving an empty space within the 
Bowman’s capsule (Figure 4, green arrow). Besides, the basement membrane of the 
glomeruli was thickened in the BL6-STZ mice (Figure 4, AB-PAS). Changes in the 
structure of the glomeruli affected the function of the kidney, which was assessed by 
increased albumin output in the urine (0.4 +/- 0.4 vs 1.4 +/- 0.5 µg/ 24 h/ g BW, p < 
0.001) and hyperfiltration indicated by decreased plasma cystatin C levels (5.4 +/- 0.6 
vs 4.5 +/- 0.6 µg/ml, p < 0.05), (Table 5). In the kidney of the db/db mice, loss of 
epithelial cells, increase in space of the Bowman’s capsule and thickening of the 
basement membrane were not present. Despite unchanged morphology of the 
glomeruli, the function of the kidney changed as shown by increased albumin 
secretion (0.7 +/- 0.5 vs 1.9 +/- 0.6 µg/ 24 h/ g BW, p < 0.05), however, without 
Results 
 30 
changes in plasma cystatin C levels (Table 5). These results suggest that both diabetic 
mouse models were affected by early stages of nephropathy.  
 
Figure 4. IHC stainings of the kidney: basement membrane thickening and loss of epithelial 
cells in T1D 
Representative photomicrographs of one glomerulus  with vas afferens und 
efferens. Of each experimental group 3 kidneys were stained with hematoxylin and 
eosin (HE), Alcian blue/periodic acid –Schiff (AB-PAS) and (Masson’s) trichrome . 
Orange arrow indicates parietal epithelial cells. Green arrow indicates thickening 
of basement membrane and increase in space of the Bowman’s capsu le. Original 
magnification x20.  
Due to the limited amount of material, no IHC staining of the heart was performed.  
4.1.2 Intracellular metabolite concentrations  
Despite an increase in plasma glucose (Table 5), intracellular glucose levels were 
decreased in the liver of the BL6-STZ mice (31.9 +/- 7.7 vs 24.9 +/- 5.3 nmol/mg 
tissue, p < 0.05) and remained unchanged in the liver of the db/db mice (Figure 5). 
Unlike in the liver, glucose concentrations were increased in the kidney of both 
diabetic models (type 1: 1.0 +/- 0.3 vs 19.3 +/- 0.7 nmol/mg tissue, p < 0.001,        
type 2: 0.8 +/- 0.3 vs 3.6 +/- 0.3 nmol/mg tissue, p < 0.001). In the liver of the        
BL6-STZ mice the concentration of malate and succinate, substrates of the TCA cycle, 
remained unchanged. However, in the liver of the db/db mice the levels of malate 
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decreased (1.0 +/- 0.2 vs 0.4 +/- 0.1 nmol/mg tissue, p < 0.001) and the levels of 
succinate showed a tendency to increase (0.09 + /- 0.01 vs 0.29 +/- 0.18 nmol/mg 
tissue, p = 0.06). In the kidney the levels of malate did not change in any of the 
models. The levels of succinate were unchanged in the kidney of the BL6-STZ model 
but showed a tendency to decrease in the db/db model (0.4 +/- 0.2 vs 0.2 +/- 0 
nmol/mg tissue, p = 0.07).  
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Figure 5. Changes in intracellular metabolite concentrations in liver and kidney 
(A/B)  Intracellular glucose, (C/D)  malate and (E/F)  succinate concentrations were 
quantified by liquid chromatography. For type 1 and type 2 diabetic study groups  
n = 6 and 5, respectively. Data is expressed as mean +/- SD. For statistical analysis 
two sided t-test was applied * p < 0.05 and *** p < 0.001 vs non-diabetic control.  
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4.1.3 Mitochondrial function  
Mitochondrial ATP production, in response to the complex I substrate malate, did 
not change in the heart of the BL6-STZ or the db/db mice when compared to the 
respective controls, which were set to 1 (Figure 6.A). In the liver, ATP production did 
not change in the BL6-STZ mice but showed a tendency to increase in the db/db 
mice (1.7 +/- 0.7 fold change, p = 0.1), (Figure 6.B). Renal mitochondria of both 
models did not show changes in ATP production (Figure 6.C).  
Mitochondrial ATP production, in response to the complex II substrate succinate, 
was unchanged in the heart of the BL6-STZ mice and decreased in the db/db mice         
(0.7 +/- 0.2 fold change, p < 0.05), (Figure 6.D). In the liver, ATP production did not 
change in the BL6-STZ mice but showed a tendency to increase in the db/db mice 
(2.0 +/- 0.9 fold change, p = 0.07), (Figure 6.E). Renal mitochondria of the BL6-STZ 
mice showed increased ATP production (1.3 +/- 0.1 fold change, p < 0.05) whereas 
ATP production remained unchanged in the db/db mice (Figure 6.F).  
 
Figure 6. ATP production in isolated mitochondria of heart, liver and kidney 
ATP production was measured with a luminescent assay in (A)  heart, (B)  l iver and 
(C) kidney using malate, glutamate and ADP as substrates for complex I. Using 
succinate and ADP as substrates for complex II ATP production was measured in 
(D)  heart, (E)  l iver and (F) kidney. For type 1 and type 2 diabetic study groups       
n = 10 or 5. Data is expressed as mean +/- SD. For statistical analysis the non-
diabetic controls were set 1 and one sample  t-test was applied * p < 0.05.  
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In the liver, the AMP level did not change in the BL6-STZ mice but decreased in the 
db/db mice (654 +/- 92 vs 475 +/- 50 pmol/mg tissue, p < 0.01), (Figure 7.A). ADP and 
ATP levels as well as energy charge did not change in the liver of any model (Figure 
7.C, E, G). In the kidney of the BL6-STZ mice, AMP levels showed a tendency to 
increase (474 +/- 129 vs 658 +/- 260 pmol/mg tissue, p < 0.15), but no change in 
AMP levels were observed in the kidney of the db/db mice (Figure 7.B). ADP levels 
showed a tendency to decrease in the kidney of the BL6-STZ mice (344 +/- 151 vs 
202 +/-11 pmol/mg tissue, p < 0.1) but remained unchanged in the db/db mice 
(Figure 8.D). ATP levels showed a tendency to decrease in the BL6-STZ mice (138 +/- 
79 vs 77 +/- 47 pmol/mg, p < 0.15) but remained unchanged in the db/db mice 
(Figure 7.F). Despite trends of changed nucleotide levels, the overall energy charge 
was unchanged in both models (Figure 7.H). This suggests, that the mitochondria 
change their function and adapt to the diabetic conditions and thus preserve the 
cellular energy homeostasis. 
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Figure 7. Changes in intracellular metabolite concentration in liver and kidney 
(A/B)  AMP, (C/D) ADP and (E/F)  ATP concentrations were quantified by liquid 
chromatography coupled fluorescence detection . (G,H)  Energy charge was 
calculated applying the following formula: ([ATP] + 0.5 [ADP]) x ([ATP] + [ADP] + 
[AMP]) -1. For type 1 and type 2 diabetic groups n = 6 and 5, respectively. Data is 
expressed as mean +/- SD. For statistical analysis two sided t-test was used.          
** p < 0.01 vs non-diabetic control.  
Results 
 36 
Mitochondrial function was analyzed with respect to O2 consumption. Using malate 
as substrate for complex I, O2 consumption was unchanged in the heart, liver and 
kidney of both diabetic models (Figure 8.A-C).  
Using succinate as substrate for complex II, O2 consumption was decreased in the 
heart of the BL6-STZ mice (0.06 +/- 0.04 fold change, p < 0.001) as well as in the 
db/db mice (0.68 +/- 0.07 fold change, p < 0.01), (Figure 8.D). In the liver, O2 
consumption showed a tendency to increase in the BL6-STZ mice (4.4 +/- 1.7 fold 
change, p = 0.07) and was increased in the db/db mice (10.3 +/- 5.4 fold change,        
p < 0.05), (Figure 8.E). In the kidney of the BL6-STZ mice, O2 consumption remained 
unchanged whereas it was decreased in the db/db mice (0.3 +/- 0.2 fold change,       
p < 0.001), (Figure 8.D).  
 
Figure 8. O2 consumption in isolated mitochondria of heart, liver and kidney 
O2 consumption was measured with a fluorescent assay in (A)  heart, (B)  liver and 
(C)  kidney using malate, glutamate and ADP as substrates for complex I. Using 
succinate and ADP as substrates for complex oxygen consumption was measured in 
(D)  heart, (E)  l iver and (F)  kidney. For type 1 and type 2 diabetic study groups       
n = 10 and 5, respectively. Data is expressed as mean +/- SD. For statistical 
analysis the non-diabetic controls were set 1 and one sample  t-test was applied    
* p < 0.05, ** p < 0.01, *** p < 0.001.  
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The majority of the differences between control and diabetic mice with regard to 
ATP production and O2 consumption were observed using succinate as a substrate 
for the ETC, suggesting that the function of complex II was altered in the 
mitochondria of diabetic animals. Moreover, it has been shown that the effect of 
diabetes on the function of the mitochondria was organ- and model-dependent. 
4.1.4 Mitochondrial ROS production 
Using the complex I substrate malate, O2
- production did not change in cardiac 
mitochondria of the BL6-STZ mice. However, O2
- production was decreased in 
cardiac mitochondria of the db/db mice (0.87 +/- 0.02 fold change, p < 0.01),     
(Figure 9.A). In the liver and kidney of both models O2
- production did not change 
(Figure 9.B + C).  
 
Figure 9. Production of O2
- in isolated mitochondria of heart, liver and kidney 
O2
-
 was quantified as NBT-diformazan formation in isolated mitochondria of (A)  
heart, (B)  l iver and (C)  kidney using malate, glutamate and ADP as substrates for 
complex I. Using succinate and ADP as substrates for complex II ATP production 
was measured in (D)  heart, (E)  liver and (F)  kidney. For type 1 and type 2 diabetic 
study groups n = 6 and 5, respectively. Data is expressed as mean +/- SD. For 
statistical analysis the non-diabetic controls were set 1 and one sample  t-test was 
applied * p < 0.05, ** p < 0.01.  
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Using the complex II substrate succinate, O2
- production did not change in the 
cardiac mitochondria of the BL6-STZ mice but decreased in the db/db mice                
(0.8 +/- 0.1 fold change, p < 0.05), (Figure 9.D). Regarding the liver, O2
- production 
was slightly increased in the BL6-STZ mice (1.2 +/- 0.2 fold change, p < 0.05) as well 
as in the db/db mice (1.4 +/- 0.1 fold change, p < 0.01), (Figure 9.E). O2
- production 
remained unchanged in isolated mitochondria of the kidney of both models when 
compared to their respective controls. 
The production of H2O2 was analyzed to rule out the possibility that the excess in O2
- 
was detoxified by SOD. Using malate as a substrate, H2O2 production did not change 
in the heart of any of the analyzed models (Figure 10.A). H2O2 production was also 
not changed in the liver of the BL6-STZ mice but increased in the db/db mice               
(1.5 +/- 0.1 fold change, p < 0.01), (Figure 10.B).  
 
Figure 10. Production of H2O2 in isolated mitochondria of heart, liver and kidney 
H2O2-induced increase in f luorescent intensity of H 2-DCF was measured in isolated 
mitochondria of (A)  heart, (B)  liver and (C)  kidney using malate, glutamate and 
ADP as substrates for complex I. Using succinate and ADP as substrates for 
complex II H2O2 production was measured in (D)  heart, (E)  liver and (F)  kidney. For 
type 1 and type 2 diabetic study groups n = 10 and 5, respectively. Data is 
expressed as mean +/- SD. For statistical analysis the non-diabetic controls were 
set 1 and one sample t-test was applied ** p < 0.01.  
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In the kidney, H2O2 production decreased in the BL6-STZ mice (0.81 +/- 0.26 fold 
change, p < 0.05) but remained unchanged in the db/db mice. Using succinate, H2O2 
production remained unchanged in the heart of both models (Figure 10.D). In the 
liver, H2O2 production did not change in the BL6-STZ mice but showed a tendency to 
increase in the db/db mice (1.4 +/- 0.3 fold change, p = 0.06), (Figure 10.E). In the 
kidney of both models H2O2 production remained unchanged (Figure 10.F). 
4.2 Is there a ROS-independent activation of the pathways of 
hyperglycemic damage in early nephropathy? 
Diabetes-induced changes of mitochondrial function and ROS production were found 
to be not only model, but also tissue dependent. In general, the changes observed 
were not associated with each other, i.e. increased mitochondrial function was not 
associated with increased ROS production, which is in contradiction to the unifying 
theory. This lack of association was particularly evident in the kidney, which despite 
having increased albumin secretion, an indication of the early stages of nephropathy, 
as well as increased intracellular glucose, showed increased mitochondrial function 
but no increased ROS production. Further analysis, with respect to the antioxidant 
defenses, as well as activation of the four pathways of cellular dysfunction, as 
described by the unifying theory, was therefore performed in the kidney. 
4.2.1 The antioxidant defense mechanisms were not increased 
The mRNA levels of the cytosolic enzyme to detoxify O2
-, Sod1 decreased in the     
BL6-STZ mice (1 +/- 0.2 vs 0.6 +/- 0.3 fold change, p < 0.05) but remained unchanged 
in the db/db mice. The mRNA expression levels of all other antioxidant genes 
including Sod2, Cat, Gpx1 and Gpx4 did not change in any of the mouse models 
(Figure 11.A). The change in Sod1 mRNA level was not reflected in the protein level, 
which remained unchanged in the BL6-STZ mice, however, SOD1 protein level 
decreased in the db/db mice (1 +/- 0.3 vs 0.3 +/- 0.2 fold change, p < 0.5) despite 
unchanged mRNA levels (Figure 11.B + C). Protein levels of SOD2, the isoform 
located in the mitochondria, remained unchanged in both models and was 
associated with unchanged total SOD activity (Figure 11.B, D + E).  
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As H2O2 production was unchanged or decreased in the kidney, protein levels and 
activity of the H2O2 detoxifying enzyme CAT were also analyzed. CAT protein levels 
were decreased in the BL6-STZ mice (1 +/- 0.1 vs 0.4 +/- 0.1 fold change, p < 0.01) 
and the db/db mice (1 +/- 0.1 vs 0.7 +/- 0 fold change, p < 0.01), (Figure 11.B + F). 
Assessing activity, the decrease in CAT protein levels was only reflected in the db/db 
mice (1 +/- 0.1 vs 0.7 +/- 0.1 fold change, p < 0.01) but not in the BL6-STZ mice          
(1 +/- 0.3 vs 0.9 +/- 0.1 fold change), (Figure 11.G).  
 
Figure 11. Analysis of the antioxidant status in the kidney of type 1 and type 2 diabetic 
mouse models 
(A)  Gene expression (B, D, E)  SOD1 and SOD2 protein levels and total activities (C, 
D, F) CAT protein level and activity were measured using qPCR, WB analysis and 
spetrophotometrical assays. H3  of one representative WB is shown. For type 1 and 
type 2 diabetic study groups n = 8 or 4  (mRNA), n = 4 (protein) and n = 5  or 4 
(activity). Data is expressed as mean +/- SD. For statistical analysis two sided         
t-test was applied * p < 0.05, ** p <  0.01 vs non-diabetic control.  
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As the activity of antioxidant enzymes has been shown to correlate negatively with 
the production of ROS, it can be concluded, that the production of O2
- was 
unchanged in both models. Unchanged CAT activity suggests that the H2O2 levels 
remained unchanged in the kidney of the BL6-STZ mice. However, H2O2 production 
seems to be increased in the db/db mice as the CAT activity was decreased in this 
model.  
4.2.2 GAPDH was not inactivated  
GAPDH protein levels increased in the cytosol of renal cells in the BL6-STZ mice        
(1 +/- 0.8 vs 9.3 +/- 5.7 fold change, p < 0.05) and in the db/db mice (1 +/- 0.4 vs 2.7 
+/- 0.2 fold change, p < 0.01), (Figure 12.A-D). However, the total activity of cytosolic 
GAPDH remained unchanged (Figure 12.E). Regarding nuclear GAPDH, neither 
protein nor activity could be detected in the nuclear fraction (Figure 12.C + D). 
 
Figure 12. Cytosolic and nuclear distribution and activity of GAPDH in the kidney of type 1 
and type 2 diabetic mouse models  
(A, B)  GAPDH protein level  in total lysate as well as in (C,D) cytosolic and nuclear 
fraction in (C)  BL6-STZ and (D) db/db mice were determined using WB analysis. (E)  
GAPDH activity was measured in the cytosolic fraction using a spectro-
photometrical assay. Nuclear activity could not be determined. For type 1 and 
type 2 diabetic study groups n = 4 (protein) and n = 5 or 4 (activity). Data is 
expressed as mean +/- SD. For statistical analysis two sided  t-test was applied * p 
< 0.05, ** p < 0.01 vs non-diabetic control.   
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4.2.3 The PKC pathway was not activated  
The protein levels of PKC- and PKC- did not change in the total cell extract of the     
BL6-STZ mice (Figure 13.A-C). These unchanged protein levels were reflected in 
unchanged total PKC activity in the cytosol of the BL6-STZ mice (Figure 14.D). In the 
db/db model, however, PKC- levels decreased (1 +/- 0.1 vs 0.4 +/- 0.4 fold change, 
p < 0.05) whereas PKC- levels increased (1 +/- 0.3 vs 1.7 +/- 0.3 fold change,              
p < 0.05) in the total cell extract (Figure 13.A–C). These uneven changes were 
accompanied by unchanged total PKC activity in the cytosol (Figure 13.D).  
Figure 13. PKC expression and activity in the kidney of type 1 and type 2 diabetic mice  
(A, B, C)  PKC- and PKC- protein levels were determined using WB analysis. For 
better visualization (not for analysis) of PKC -, background was subtracted in the 
BL6-ctrl and the BL6-STZ mice. H3 of one representative WB is shown. (D)  Total 
PKC activity was measured using an ELISA utilizing a synthetic peptide as a 
substrate for PKC. For type 1 and type 2 diabetic study groups n  = 4 (protein) and 
n = 5 or 4 (activity). Data is expressed as mean +/- SD. For statistical analysis two 
sided  t-test was applied * p < 0.05vs non-diabetic control.   
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4.2.4 The production of the AGE precursor MG was not increased 
MG showed a tendency to increase in the BL6-STZ mice (474 +/- 129 vs 658 +/- 260 
pmol / mg tissue, p = 0.15) but remained unchanged in the db/db mice (Figure 14.A). 
Increased MG formation is accompanied by decreased activity of the glyoxalase 
system (Rabbani and Thornalley, 2011; Vander Jagt, 2008). Therefore, changes 
regarding Glo1, the first enzyme of MG detoxification, were further assessed. Glo1 
mRNA and protein levels as well as the activity were not increased in any of the 
diabetic models (Figure 14.B–E).  
 
Figure 14. No changes in the AGE pathway in the kidney of type 1 and type 2 diabetic 
mouse models 
(A)  MG levels were determined using LC-MS/MS. (B)  Glo1 gene expression, (C, D)  
protein level and (E) activity were measured using qPCR, WB analysis and a 
spetrophotometrical assay. For type 1 and type 2 diabetic study groups n = 6 or 5 
(MG level), n = 8 or 4 (mRNA), n = 4 (protein), n = 5 or  4 (activity). Data is 
expressed as mean +/- SD. For statistical analysis two sided  t-test was applied. 
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4.2.5 The polyol pathway was altered in a model-dependent manner: increase in 
type 1 and decrease in type 2 diabetes 
Fructose, the endproduct of the polyol pathway, was increased in the BL6-STZ mice 
(1 +/- 0.27 vs 10.6 +/- 4.35 fold change, p < 0.001) but decreased in the db/db mice 
(1 +/- 0.27 vs 0.56 +/- 0.21 fold change, p < 0.05), (Figure 15). 
 
Figure 15. Model dependent alteration of the polyol pathway in the kidney of type 1 and 
type 2 diabetic mouse models  
Intracellular fructose levels were quant ified by liquid chromatography. For type 1 
and type 2 diabetic study groups n = 6 or  4. Data is expressed as mean +/- SD. For 
statistical analysis two sided t-test was applied. * p < 0.05, *** p < 0.001 vs non -
diabetic control.  
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4.2.6 The hexosamine pathway was altered in a model-dependent manner: 
increase in type 1 and decrease in type 2 diabetes 
O-GlcNAc modifications were increased in the BL6-STZ mice (1 +/- 0.6 vs 3.5 +/- 1.0 
fold change, p < 0.01) but decreased in the db/db mice (1 +/- 0.2 vs 0.4 +/- 0.1 fold 
change, p < 0.01), (Figure 16.A+B). This analysis showed a model-dependent change 
in the hexosamine pathway, which was independent of intracellular glucose and 
ROS-mediated inactivation of GAPDH.  
 
Figure 16. Altered O-linked β-N-acetylglucosamination in the kidney of type 1 diabetic and 
type 2 diabetic mouse models  
(A) Levels of O-GlcNAc protein modifications were determined using WB.                 
(B) Densitometry analysis of the two distinct bands showing O -GlcNAc 
modifications were performed and the fold change to the respective control was 
calculated. For type 1 and type 2 diabetic study groups n = 4. Data is expressed as 
mean +/- SD and two sided  t-test was applied for statistical analysis  ** p < 0.01 vs 
non-diabetic control.    
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4.3 Activation of NQO1 in the diabetic kidney 
It was found that the mRNA levels of Nrf2 were increased in the BL6-STZ mice           
(1 +/- 0.2 vs 1.6 +/- 0.4 fold change, p < 0.01), (Figure 17.A). As NRF2 activates the 
transcription of Nqo1, elevated mRNA levels of Nrf2 resulted subsequently in an 
increased transcription of Nqo1 in the BL6-STZ mice (1 +/- 0.3 vs 2.1 +/- 0.7 fold 
change, p < 0.01), (Figure 18.A). However, Nrf2 and Nqo1 mRNA levels remained 
unchanged in the kidney of the db/db mice (Figure 17.A). Next, it was analyzed 
whether the increase in mRNA level of Nqo1 in the BL6-STZ mice was reflected in the 
protein level. NQO1 protein levels were increased in the BL6-STZ mice (1 +/- 0.2 vs 
2.2 +/- 0.6 fold change, p < 0.05) but decreased in the db/db mice (1 +/- 0.3 vs 0.3 +/- 
0.3 fold change, p < 0.01), (Figure 17.B+C). Finally, NQO1 activity was measured and 
was found to be elevated in both diabetic models (type 1: 1 +/- 0.1 vs 2.4 +/- 0.9 fold 
change, p < 0.001 and type 2: 1 +/- 0.1 vs 1.6 +/- 0.2 fold change, p < 0.05), (Figure 
17.D). As the increase in NQO1 activity in the db/db mice was not reflected in the 
protein level, the NQO1 activity assay was performed including the specific inhibitor 
dicumarol to verify that only NQO1 activity was measured in the assay. Including the 
inhibitor, no NQO1 activity could be measured in any of the mouse models (data not 
shown).  
The total NRF2/NQO1 pathway was only increased in the type 1 diabetic model, 
however, the activity of NQO1 was increased in both models. As such, the activity of 
NQO1 was the common alteration in the type 1 and type 2 diabetic mouse models, 
which were both affected by hyperglycemia and albuminuria.  
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Figure 17. NQO1 levels and activity in the kidney of type 1 and type 2 diabetic mouse 
models  
(A)  Nrf2  and Nqo1  mRNA levels, (B, C)  NQO1 protein level and (D)  activity were 
measured using qPCR, WB and spetrophotometrical assays. For type 1 and type 2 
diabetic study groups n = 8 and 4, respectively (mRNA), n = 4 (protein) and n = 5 
and 4 respectively (activity). Data is expressed as mean +/ - SD. For statistical 
analysis two sided  t-test was applied * p < 0.05, ** p < 0.01 and *** p < 0.001 vs 
non-diabetic control.   
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5 Discussion 
5.1 Diabetes-induced mitochondrial changes are tissue-specific 
In this study, diabetes-induced mitochondrial changes were studied in 2 
experimental murine models with 3 months of diabetes during which robust 
hyperglycemia was established. It was shown that changes to the mitochondria were 
tissue-, model- and substrate-specific and that the changes observed were in general 
not associated with each other. As such decreased O2 consumption was not reflected 
in ATP production in the kidney of the db/db mice and increased O2 consumption 
was not reflected in ATP and ROS production in the kidney of the STZ-treated mice. 
Moreover, there was no reflection of the intense increase in O2 consumption in ATP 
production in the liver. This lack of association is in contradiction to the unifying 
theory, which describes a connection of elevated glucose levels to increased 
mitochondrial function. This subsequently leads to increased ROS levels, which cause 
cellular damage leading to the development of diabetic complications. However, the 
tissue specific and unassociated changes of the mitochondria, observed in this study, 
suggest that there is no unified response of the mitochondria to the diabetic 
condition.  
Isolated mitochondria of the heart showed differences between the diabetic models 
with regard to ATP and O2
- production. However, O2 consumption was decreased in 
both models when succinate was used as a substrate for the ETC. Decreased O2 
consumption is consistent with previous studies in type 1 and type 2 diabetic models 
(Boudina et al., 2007; Bugger et al., 2008). During diabetes, it has been reported that 
the expression of the glucose transporter Glut4 was decreased in the heart resulting 
in increased fatty acid utilization (Wright et al., 2008). Fatty acids, however, are 
energetically detrimental as more O2 is required for their oxidation, leading to 
increased myocardial O2 consumption with reduced cardiac efficiency. This was 
shown in a diabetic rodent model as well as in insulin resistant and type 1 diabetic 
patients (How et al., 2006; Peterson, 2004; Peterson et al., 2008). Moreover, 
increased cardiac oxidation of fatty acids was associated with heart failure. A 
randomized clinical trial showed that partial inhibition of fatty acid oxidation 
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improved ventricular function in patients with heart failure (Fragasso et al., 2006). 
Studies on O2 consumption in saponin-permeabilized cardiac fibers of diabetic 
models showed that the mitochondria adapt to changes in substrate availability 
(Boudina et al., 2007; Bugger et al., 2008). Using glucose-derived substrates, O2 
consumption was reduced in Ins2+/- Akita mice after 10 weeks of diabetes. After 
longer duration of diabetes (24 weeks) this decrease was associated with decrease in 
ATP production. However, using fatty acids as substrates, neither O2 consumption 
nor ATP production were changed (Bugger et al., 2008). O2 consumption and ATP 
production were also decreased in saponin-permeabilized cardiac fibers of the db/db 
mice when glucose-derived substrates were used. The use of fatty acids, however, 
only decreased O2 consumption and not ATP production in this model (Boudina et 
al., 2007). Both studies associated impaired oxidative phosphorylation with an 
increase in uncoupling proteins to adapt to the changes in substrate (Boudina et al., 
2007; Bugger et al., 2008). These studies have shown, that the change of substrate 
availability from glucose to fatty acids led to a higher demand of O2 and reduced 
cardiac efficiency. The mitochondria therefore adapted to this change with 
uncoupling as to have a better applicability for fatty acids. This would suggest that 
the decrease in O2 consumption of the heart observed in the current study was 
associated with an adaption to fatty acids as substrates for oxidation. As such, the 
absence of glucose rather than its accumulation is involved in changes of the cardiac 
mitochondria leading to the development of cardiac complications in diabetes.    
In the liver, despite increased plasma glucose, the glucose concentration was not 
increased in both diabetic models. However, O2 consumption and O2
- production 
increased in the isolated mitochondria when succinate was used as a substrate. 
Increased respiration in the liver is consistent with previous studies. In STZ-induced 
type 1 diabetic rats, elevated levels of complex I and II, but decreased levels of 
complex III and IV of the ETC were associated with increased O2 consumption and 
ROS production of the mitochondria (Raza et al., 2011). O2 consumption was 
increased in the mitochondria of wild type mice affected by high fat diet-induced 
T2D. Quantitative proteomic analysis showed that the functional changes were 
associated with elevated proteins of metabolic pathways such as the TCA cycle, fatty 
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acid oxidation and oxidative phosphorylation (Guo et al., 2013). Increased expression 
of OXPHOS genes was also analyzed by microarray hybridization in the liver of insulin 
resistant mice. This increase was associated with elevated mitochondrial respiration 
(Buchner et al., 2011). Moreover, a clinical study showed increased transcription of 
OXPHOS genes in the liver of insulin-resistant patients (Misu et al., 2007). All of these 
studies associated altered insulin signaling with changes in the transcription of 
OXPHOS genes and subsequently increased mitochondrial respiration. This would 
suggest, that impaired insulin signaling rather than increased glucose levels can 
result in increased levels of OXPHOS proteins, which induce elevated mitochondrial 
O2 consumption and O2
- production, as observed in the current study. 
The kidney of both diabetic models showed increased cellular glucose levels and 
increased albumin secretion. However, the changes in the mitochondria were model 
dependent. ATP production and O2 consumption were increased in the type 1 
diabetic model, whereas O2 consumption decreased in the type 2 diabetic model. 
Increased glucose levels, therefore, cannot be responsible for the model-dependent 
differences observed. Moreover, increased glucose cannot be considered to cause 
mitochondrial ROS production as despite increased glucose, both models, showed 
no increase in mitochondrial O2
- and H2O2 production. Unchanged mitochondrial 
ROS production, however, is contradictory to the majority of studies, which have 
reported an increase in renal ROS production ex vivo (Abdo et al., 2014; de Cavanagh 
et al., 2008; Coughlan et al., 2016; Fujita et al., 2012; Palsamy and Subramanian, 
2011), (Appendix, Table 8). These studies associate elevated ROS levels with the 
development of cellular damage. However, Dugan et al. showed, that ROS 
production decreased in vivo and in isolated mitochondria of STZ-induced diabetic 
mice. Moreover, decrease in a ROS detoxification enzyme in diabetic Sod2+/- mice did 
not worsen albumin secretion. In this model, increase in O2
- were even associated 
with reduction of albumin secretion (Dugan et al., 2013). These studies suggest that 
the cellular response to ROS exposure is not linear but dose-dependent with low 
doses of ROS being beneficial but higher doses being harmful (Ristow and 
Schmeisser, 2014). In the current study, changes in mitochondrial function were 
analyzed after 3 months of diabetes. At this time point mitochondrial ROS 
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production was not increased. However, it cannot be ruled out that ROS levels 
increase after longer duration of diabetes and contribute to the pathogenesis of 
diabetic complications. Therefore, ROS production should be analyzed after a longer 
duration of diabetes to determine whether increased oxidative stress is involved in 
later stages of nephropathy.  
The current study analyzed functional changes in isolated mitochondria using 
previously described protocols (Will et al., 2007). However, it needs to be considered 
that potential diabetes-induced changes of cofactors like the NAD+/NADH ratio, 
which can exist in vivo, are not represented in the isolated system. As such, it cannot 
be excluded that the experimental set up did not reflect the exact conditions found 
in vivo. As such, improper buffer composition could explain, why most changes in 
mitochondrial function were only detectable when succinate was used as a substrate 
for the ETC. The results obtained in the current study should, therefore, be verified 
in a now available transgenic mouse expressing a redox-sensitive H2O2 biosensor, 
which is targeted to the mitochondria (Fujikawa et al., 2016). 
5.2 The unifying theory is not applicable to the early stages of 
nephropathy 
The kidneys of both diabetic models were affected by albuminuria and by increased 
levels of intracellular glucose. Despite the changes in mitochondrial function, ROS 
production was not increased in the mitochondria. Oxidative stress was also 
analyzed in renal tissue. As ROS have a short half-life, they are precarious to 
measure in whole tissue. Previous studies have shown that increased ROS levels 
correlate negatively with the activity of the antioxidant defense mechanism 
(Furukawa et al., 2004; Sam et al., 2005). Therefore, changes in the antioxidant 
defense system were measured in this study to assess the oxidative stress level in 
renal cell lysate. SOD activity remained unchanged in both models whereas CAT 
activity decreased in the db/db model suggesting that there is no oxidative stress in 
the STZ-model and mild oxidative stress in the db/db model. However, the 
potentially increased H2O2 levels in the db/db mice did not result in ROS-induced 
inactivation of GAPDH activity. If the unifying theory were correct the pathways of 
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hyperglycemic damage could not become activated without ROS-mediated 
inactivation of GAPDH activity. As both diabetic models were affected by early stages 
of nephropathy, it was therefore analyzed, whether there is a GAPDH independent 
activation of the major pathways described for cellular damage induced by 
hyperglycemia. Regarding the triosephosphate-depending pathways, total PKC 
activity was unchanged. Moreover, MG was not significantly increased and the 
activity of its detoxifying enzyme remained unchanged, suggesting that the AGE 
pathway remained inactivated as well. As such the triosephosphate-depending 
pathways of the unifying theory (PKC and AGE) remained inactivated without ROS-
mediated decrease in GAPDH activity. This is in agreement with the unifying theory, 
suggesting that indeed ROS is required for the inactivation of GAPDH and 
subsequent activation of the PKC and the AGE pathway. The development of 
nephropathy without activation of the pathways of hyperglycemic damage, 
however, is inconsistent with this theory (Brownlee, 2001). The inconsistency with 
the unifying theory would explain, why most clinical trials using antioxidants or 
inhibitors of the pathways showed no benefit with regard to the pathogenesis of 
nephropathy. The urinary albumin secretion rate was decreased in a small trial 
treating T2D patients with a combination of the antioxidants vitamin C and vitamin E 
for 4 weeks (Gaede et al., 2001). However, a larger cohort, involving more than 3000 
diabetic patients, showed no benefit on nephropathy or cardiovascular outcome 
after more than 4 years of treatment with vitamin E (Lonn et al., 2002). Treatment 
with the synthetic vitamin B1 benfotiamine, an AGE lowering drug, (900 mg/day) for 
3 months showed no benefit of nephropathy symptoms in T2D (Alkhalaf et al., 
2010). Moreover, the PKC inhibitor ruboxistaurin, did not improve symptoms of 
nephropathy in a large diabetic study cohort after 3 years of treatment (Tuttle et al., 
2007, 2015). Unlike in the kidney, however, studies have shown the activation of 
pathways of hyperglycemic damage in other organs such as retina and neurons 
(Hammes et al., 2003; Madsen-Bouterse et al., 2010; Nakamura et al., 1999; 
Obrosova et al., 2004). In these tissues therapies inhibiting the activation of the 
pathways of hyperglycemic damage were beneficial. The PKC inhibitor ruboxistaurin 
has been shown to have a beneficial effect on vision loss in the context of 
retinopathy (Aiello et al., 2011). Regarding neuropathy, Casellini et al. reported 
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improved symptoms of peripheral neuropathy after 6 months of treatment with 
ruboxistaurin (Casellini et al., 2007). These studies provide further support that 
diabetes induces organ-specific changes, which lead to the activation of pathways 
described for hyperglycemia-induced cellular damage in tissues including neurons 
and retina. In early stages of nephropathy, however, ROS-induced activation of the 
pathways was not detected in total kidney lysate. The kidney is composed of 
different cell types and in this work a mixture of all renal cells was analyzed. As such, 
the proximal tubule epithelial cells, which are the most abundant cell type in the 
kidney, represent the majority of cells analyzed in total kidney lysates (Nakhoul and 
Batuman, 2011). Further studies are therefore required to determine whether ROS-
mediated activation of the pathways of cellular damage is present in a small subset 
of distinct cell types in the diabetic kidney. 
 
The pathways upstream of triosephosphates were activated in a model-dependent 
manner. Despite the symptoms of nephropathy in both models, the levels of 
fructose, the endproduct of the polyol pathway, were increased in the STZ-model 
and decreased in the db/db model. According to the unifying theory, glucose is 
directly utilized in the polyol pathway. Despite increased renal glucose levels in both 
models, however, only the type 1 diabetic model showed ROS-independent 
activation of the polyol pathway. As such the activation of the polyol pathway 
cannot be glucose dependent, which is consistent with the previously reported high 
Km value of aldose reductase, the first enzyme of the polyol pathway, for glucose    
(Km = 100 mM) (Bohren et al., 1992). This suggests, that another substrate has been 
used by aldose reductase to increase the levels of fructose in the type 1 diabetic 
model. Further studies are, therefore, required to determine the substrate for the 
activation of the polyol pathway in T1D.  
The activation of the hexosamine pathway was also model-dependent. The 
endproduct of this pathway is uridine diphosphate N-actelyglucosamine, which can 
modify proteins resulting in O-linked β-N-acetylglucosamination (O-GlcNAc). The O-
GlcNAc levels were increased in the type 1 diabetic but decreased in the type 2 
diabetic model. Despite elevated renal glucose levels in both models, the changes of 
the hexosamine pathway were model-dependent and can, therefore, not be 
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associated with intracellular glucose concentrations or ROS- mediated inactivation of 
GAPDH.  
The model-dependent changes in the polyol and hexosamine pathway, which were 
first reported in this study, are inconsistent with the unifying theory. As both models 
are affected by increased renal glucose concentrations, the differences in the 
activation of the pathways cannot be explained by hyperglycemia. Moreover, the 
polyol and the AGE pathway cannot be considered to be involved in the 
pathogenesis of diabetic kidney disease as these pathways were only activated in the 
type 1 diabetic model, whereas both models were affected by symptoms of early 
nephropathy. As such the mechanisms involved in the development of diabetes-
associated kidney disease are still not fully understood.  
5.3 Increased NQO1 activity in the early stages of nephropathy 
The unifying theory cannot be applied to the development of the symptoms of early 
nephropathy, as oxidative stress is not increased in the diabetic kidney. As such 
other mechanisms must be involved in the pathogenesis of diabetic kidney disease. 
Recently, it has been published, that NQO1 activity attenuates kidney injury (Oh et 
al., 2014). NQO1 is a classical reporter gene for the activity of NRF2, a transcription 
factor which is induced by cellular stress. However, the type of cellular stress, which 
activates NRF2, is under debate. Studies have reported that NRF2 is activated by 
oxidative stress but also by ROS-independent pathways such as during the 
inflammatory response (Nguyen et al., 2009; Rushworth et al., 2008). As diabetes is 
associated with chronic inflammation, the activation of the NRF2/NQO1 pathway 
was analyzed as a possible oxidative stress-independent mechanism activated in 
nephropathy. The mRNA levels of NRF2 and NQO1 were increased in the kidney of 
the type 1 but not of the type 2 diabetic model. Increased levels of NRF2 and NQO1 
in T1D are consistent with previous studies, which reported elevated NRF2 and 
NQO1 levels in kidneys of diabetic patients with proteinuria and type 1 diabetic wild 
type mice (Jiang et al., 2010). In the current study, however, mRNA and protein 
levels of NRF2 and NQO1 were not increased in T2D. Nevertheless, the activity of 
NQO1 was increased in both diabetic models. Increased NQO1 activity suggests that 
there is an oxidative stress independent cellular stressor in diabetes, which is not 
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activating the pathways of the unifying theory but is leading to the activation of 
NRF2 and NQO1. NQO1 utilizes NAD(P)H and catalyzes the two electron reduction of 
quinones to quinols whereby the cellular NAD(P)+/NAD(P)H ratio is increased (Ross 
and Siegel, 2004). Ubiquinone levels have been reported to be increased in the 
plasma of patients with T2D (Ates et al., 2013). Moreover, treatment of Ins2+/- Akita 
mice with the mitochondria-targeted ubiquinone MitoQ, a substrate of NQO1, 
improved glomerular function and albumin secretion (Chacko et al., 2010). Increased 
activity of NQO1 and increased NAD(P)+/NAD(P)H ratio were also associated with 
improved serum creatinine levels and decreased kidney injury (Oh et al., 2014). 
These studies suggest, that increased levels of ubiquinone result in increased activity 
of NQO1 and increased NAD(P)+/NAD(P)H ratio causing beneficial effects to prevent 
the development of diabetic complications. Despite increased activity of NQO1, 
however, the diabetic mice, assessed in this study, developed albuminuria. As such, 
a NQO1 knockout model needs to be assessed in the context of diabetes to 
determine whether increased activity of NQO1 has a beneficial effect in the 
development of nephropathy and whether NQO1 could be a promising target in the 
development of an anti-diabetic drug.   
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6 Summary 
The development of diabetic complications has been associated with glucose-
induced increased mitochondrial ROS production and subsequently activation of four 
major pathways described in the unifying theory such as the polyol, the hexosamine, 
the protein kinase C (PKC) and the advanced glycation endproduct (AGE) pathway. 
However, intensive glucose therapy was only beneficial for a small subset of 
patients. Moreover, experimental studies have not been able to clarify whether the 
function of the mitochondria was changed in diabetes resulting in increased ROS 
production. The results depended on the tissue assessed and methods used. This 
study therefore, used the same methods to analyze mitochondrial changes in 
different tissues of 3 months diabetic streptozotocin (STZ)-induced C57BL/6 and 
db/db mice, along with the respective age-matched controls. Diabetes-induced 
changes of isolated mitochondria were model, tissue and substrate specific. 
However, some changes were found to be independent of the diabetes type. These 
changes included decreased O2 consumption in the diabetic heart as well as 
increased O2 consumption and O2
- production in the diabetic liver. Regarding the 
kidney of both models, ROS production remained unchanged, despite elevated renal 
glucose levels and increased albumin secretion in the urine. As a consequence of the 
absence of oxidative stress, GAPDH was not inactivated. Moreover, the PKC and the 
AGE pathway were not altered in the diabetic kidneys. Absence of activation of these 
two pathways without increase in ROS production was consistent with the unifying 
theory, however, ROS-independent development of albuminuria was not consistent 
with this theory. Moreover, it was inconsistent with the unifying theory that the 
hexosamine and the polyol pathway were ROS-independently activated in the STZ-
model. Both pathways were not activated in the db/db model and their activation 
can therefore not be involved in the development of albuminuria. As such, the 
unifying theory cannot explain the situation in the early phase of nephropathy. With 
regard to the activation of potential protective mechanism against the development 
of diabetic complications this study could show increased activation of NAD(P)H 
quinone reductase (NQO1) in the kidney of both diabetic models. Increased activity 
of NQO1 has previously been shown to mitigate kidney damage. However, the exact 
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mechanisms for this activation need to be further analyzed to determine whether 
NQO1 mitigates diabetic kidney disease and whether it is a potential target for an 
anti-diabetic therapy. 
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8 Appendix 
Table 6. ATP production and levels in heart, liver and kidney of different diabetic models 
Model 
Induction of 
diabetes 
Duration*  
weeks 
Result Substrate Reference 
Heart 
     
♂ db/db genetic T2D 4 ↓ in permeabilized tissue malate 
(Boudina et al., 
2007) 
♂ wild type mice low dose STZ2 4 ↓ in permeabilized tissue malate 
(Bugger et al., 
2012) 
♂ Ins2+/- Akita 
mice 
genetic T1D 6 ↓ in isolated mt succinate 
(Bugger et al., 
2009) 
♂ Ins2+/- Akita 
mice 
genetic T1D 6 ↔ in isolated mt malate 
(Bugger et al., 
2009) 
Liver 
     
♂ Ins2+/- Akita 
mice 
genetic T1D 6 ↔ in isolated mt 
malate or 
succinate 
(Bugger et al., 
2009) 
♂ Zucker rat genetic T2D 30 ↓ liver ATP content - 
(Raza et al., 
2015) 
♀, ♂ patients T2D - ↓ATP turnover MRS 
(Schmid et al., 
2011) 
♂ C57BL/6J HFD 30 (HFD) ↑ in isolated mt malate 
(Guo et al., 
2013) 
Kidney 
     
♂ Sprague-
Dawley rats 
single dose STZ 4-32 ↓ renal ATP content - 
(Coughlan et al., 
2016) 
♂ Ins2+/- Akita 
mice 
genetic T1D 6 ↔in isolated mt 
malate or 
succinate 
(Bugger et al., 
2009) 
♂ C57BL/6J low dose STZ2 24 ↓ mt ATP production malate (Tan et al., 2010) 
♂ Ins2+/- Akita 
mice 
genetic T1D  20 
↑glomeruli ATP content 
↓ medula ATP content 
 
(Miyamoto et 
al., 2016) 
1 of diabetes 
2 low dose STZ for 5 consecutive days 
mitochondria (mt), high fat diet (HFD), magnetic resonance spectroscopy (MRS) 
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Table 7. O2 consumption in heart, liver and kidney of different diabetic models 
Model 
Induction of 
diabetes 
Duration*  
weeks 
Result Substrate Reference 
Heart 
     
♂ db/db mice genetic T2D 4 ↓ in permeabilized tissue malate 
(Boudina et al., 
2007) 
♂ wild type mice low dose STZ2 4 
↔ in permeabilized 
tissue
malate 
(Bugger et al., 
2012) 
♂ Ins2+/- Akita 
mice 
genetic T1D 6 ↓ in isolated mt 
malate or 
succinate 
(Bugger et al., 
2009) 
♂ OVE26 mice genetic T1D 8 ↓ in isolated mt malate 
(Shen et al., 
2006) 
Liver 
     
♂ Ins2+/- Akita 
mice 
genetic T1D 6 ↔ in isolated mt 
malate or 
succinate 
(Bugger et al., 
2009) 
♂ Sprague-
Dawley rats 
single dose STZ 8 ↑ in isolated mt succinate 
(Raza et al., 
2011) 
ZDF fa/fa rats genetic T2D 11, 14 ↔ in isolated mt 
malate or 
succinate 
(Vial et al., 2016) 
♂ C57BL/6J mice HFD 30 (HFD) ↑ in isolated mt 
malate or 
succinate 
(Guo et al., 
2013) 
♀ NOD mice genetic T1D 
4 – 25 weeks 
of age 
↔ in isolated mt in non-
diabetic, pre-diabetic and 
diabetic stage 
malate 
(Malaguti et al., 
2014) 
Kidney 
     
♂ Sprague-
Dawley rats 
single dose STZ 4-32 
↑ in isolated mt (starting 
from week 16) 
malate 
(Coughlan et al., 
2016) 
♂ Ins2+/- Akita 
mice 
genetic T1D 6 ↑ in isolated mt 
malate or 
succinate 
(Bugger et al., 
2009) 
♂ Lewis rats single dose STZ 8, 24, 48 
↔ in isolated mt, week 8 
↓ in isolated mt, week 24 
and 48 
malate 
(Rosca et al., 
2005) 
1 of diabetes 
2 low dose STZ for 5 consecutive days 
mitochondria (mt), high fat diet (HFD) 
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Table 8. ROS production in heart, liver and kidney of different diabetic models 
Model 
Induction of 
diabetes 
Duration*  
weeks 
Result Substrate Reference 
Heart 
     
♂ db/db mice genetic T2D 4 ↑ mt H2O2 production
succinate + 
Omy 
(Boudina et 
al., 2007) 
♂ wild type mice low dose STZ2 4 
↔ H2O2 production in 
permeabilized fibers
succinate 
(Bugger et al., 
2012) 
♂ Lewis rats single dose STZ 10 ↑ mt H2O2 production succinate 
(Rosca et al., 
2005) 
Liver 
     
♂ Sprague-
Dawley rats 
single dose STZ 8 ↑ in isolated mt - 
(Raza et al., 
2011) 
♂ Zucker rat genetic T2D 30 
↓ total and membrane 
bound ROS production 
↔ mt ROS production 
- 
(Raza et al., 
2015) 
ZDF fa/fa rats genetic T2D 11, 14 
↓ mt H2O2 production at 
14 weeks 
malate or 
succinate 
(Vial et al., 
2016) 
♀ NOD mice genetic T1D 
4 – 25 
weeks of 
age 
↑ mt H2O2 and ROS 
production in non-diabetic 
stage 
↔ mt H2O2 and ROS 
production in pre-diabetic 
and diabetic stage 
malate 
(Malaguti et 
al., 2014) 
Kidney 
     
♂ Sprague-
Dawley rats 
single dose STZ 4-32 
↑ mt H2O2 production 
(starting from week 8) 
malate 
(Coughlan et 
al., 2016) 
♂ Sprague-
Dawley rats 
single dose STZ 12 ↑ mt H2O2 production malate 
(de Cavanagh 
et al., 2008) 
♂ C57BL/6 mice low dose STZ2 24 ↓ O2
- production in vivo 
real-time 
imaging 
(Dugan et al., 
2013) 
♂ C57BL/6 mice low dose STZ2 24 ↓ mt H2O2 production 
malate or 
succinate 
(Dugan et al., 
2013) 
♂ Ins2+/- Akita 
mice 
genetic T1D 10 ↑ glomerular O2
- level 
histo-
chemistry 
(Fujita et al., 
2012) 
♂ Ins2+/- Akita 
mice 
genetic T1D 12 
↑ increase in ROS levels in 
the tissue  
histo-
chemistry 
(Abdo et al., 
2014) 
♂ Wistar rats single dose STZ 4 
↑ mt H2O2 production in 
tissue homogenate 
cytochrome 
reduction  
(Palsamy and 
Subramanian, 
2011) 
1 of diabetes 
2 low dose STZ for 5 consecutive days 
mitochondria (mt) 
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Table 9. SOD level and activity in heart, liver and kidney of different diabetic models 
Model 
Induction of 
diabetes 
Duration* 
weeks 
Result Reference 
Heart 
    
Wistar rats 
single dose 
alloxan 
8 ↓ SOD1activity 
(Aliciguzel et al., 
2003) 
♂ db/db mice genetic T2D 4 ↑ SOD2 protein level 
(Boudina et al., 
2007) 
♂ Sprague-Dawley 
rats 
single dose STZ 4 ↑ total SOD activity 
(Strother et al., 
2001) 
♂ Wistar rats single dose STZ 24 ↔ total SOD activity 
(Naderi et al., 
2015) 
♀ Wistar rats 
single dose 
alloxan 
12 ↔ SOD1 activity 
(Godin et al., 
1988) 
Liver 
 
Wistar rats 
single dose 
alloxan 
8 ↔ SOD1 activity 
(Aliciguzel et al., 
2003) 
♂ Sprague-Dawley 
rats 
single dose STZ 1, 6 
↑ total SOD and SOD1 acitivity 
↔ SOD2 activity  
(starting form week 1) 
(Kakkar et al., 
1998) 
♂ C57BL/6N mice low dose STZ2 8 ↔ SOD2 protein level 
(Franko et al., 
2014) 
♀ Wistar rats single dose 
alloxan 
12 ↓ SOD1 activity 
(Godin et al., 
1988) 
♂ Wistar rats single dose 
alloxan 
4 
↓ Sod1 and Sod2 mRNA level 
↑ SOD1 protein level/ acitivity 
↔ SOD2 protein level/ acitivity 
(Sadi et al., 
2015) 
Kidney 
    
♂ Sprague-Dawley 
rats 
single dose STZ 4-32 ↓ SOD2 activity (starting from week 8) 
(Coughlan et al., 
2016) 
♂ Sprague-Dawley 
rats 
single dose STZ 12 ↓ SOD2 activity 
(de Cavanagh et 
al., 2008) 
Wistar rats 
single dose 
alloxan 
8 ↔ SOD1 activity 
(Aliciguzel et al., 
2003) 
♂ db/db mice genetic T2D 18 
↑ SOD1 protein level in the glomeruli 
↓ SOD1 protein level in the tubules 
↔ SOD1 activity in cortex and glomeruli 
(Barati et al., 
2007) 
♂ db/db mice genetic T2D 16 
↔ SOD1 and SOD2 activity in renal 
cortex 
(DeRubertis et 
al., 2004) 
♂ Ins2+/- Akita 
mice 
genetic T1D 10 
↔ SOD1, SOD2, SOD3 protein level 
↓ total SOD activity 
(Fujita et al., 
2012) 
♂ Sprague-Dawley 
rats 
single dose STZ 4 ↑ total SOD activity 
(Strother et al., 
2001) 
1 of diabetes 
2 low dose STZ for 5 consecutive days 
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Table 10. CAT level and activity in heart, liver and kidney of different diabetic models 
Model 
Induction of 
diabetes 
Duration* 
weeks 
Result Reference 
Heart 
    
Wistar rats 
single dose 
alloxan 
8 ↓ CAT activity 
(Aliciguzel et al., 
2003) 
♀ Wistar rats single dose 
alloxan 
12 ↑ CAT activity 
(Godin et al., 
1988) 
♀, ♂ OVE26 mice genetic T1D 20 ↑ CAT mRNA (Ye et al., 2004) 
♂ Wistar rats single dose STZ 24 ↔ CAT activity 
(Naderi et al., 
2015) 
Liver 
    
Wistar rats 
single dose 
alloxan 
8 ↑ CAT activity 
(Aliciguzel et al., 
2003) 
♂ Sprague-Dawley 
rats 
single dose STZ 1, 6 ↑ CAT activity (starting form week 1) 
(Kakkar et al., 
1998) 
♂ Sprague-Dawley 
rats 
single dose STZ 4 ↓ CAT activity 
(Strother et al., 
2001) 
♂ Zucker rat genetic T2D 30 ↔ CAT activity 
(Raza et al., 
2015) 
♀ Wistar rats single dose 
alloxan 
12 ↓ CAT activity 
(Godin et al., 
1988) 
Kidney 
    
Wistar rats 
single dose 
alloxan 
8 ↑ CAT activity 
(Aliciguzel et al., 
2003) 
♂ db/db mice genetic T2D 16 ↔ cortical CAT activity 
(DeRubertis et 
al., 2004) 
♀ Wistar rats 
single dose 
alloxan 
12 ↓ CAT activity 
(Godin et al., 
1988) 
♂ Ins2+/- Akita 
mice 
genetic T1D 12 ↓ Cat mRNA/ activity 
(Abdo et al., 
2014) 
1 of diabetes 
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